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The simplest phospholipid, lysophosphatidic acid (LPA), is a heat stable
component of serum known for its proliferative and migratory activities in cancer cells.
Strong evidence suggests that LPA production and expression of its receptors are
dysregulated in multiple human malignancies. The mechanism behind LPA-mediated
tumor cell growth and oncogenesis remains poorly understood. In this thesis project I
used ovarian and other cancer cells as a model system to examine the hypothesis that
LPA present in the tumor microenvironment is a pathophysiological determinant of
hyperactive de novo lipogenesis and aerobic glycolysis, two hallmarks of cancer cells.
We demonstrated that LPA induced proteolytic activation of sterol regulatory
element binding proteins (SREBPs) in a cancer specific manner, leading to activation of
the SREBP-FAS (fatty acid synthase) lipogenic pathway. Treatment of cancer cell lines
with LPA also led to dephosphorylation and inhibition of AMP-activated kinase (AMPK),
thereby activating acetyl CoA carboxylase (ACC). Moreover, these effects of LPA were
mediated by LPA2, a receptor subtype overexpressed in multiple cancers, providing an
explanation for the cancer specific regulation of FAS and ACC by LPA. Downstream of
the LPA2 receptor, we identified the Gα12-Rho-Rock pathway to activate SREBPs and the
Gαq-PLC (phospholipase C) pathway to inactivate AMPK. Consistent with LPA mediated
activation of the key lipogenic enzymes FAS and ACC, LPA stimulated de novo lipid
synthesis via LPA2, leading to accumulation of intracellular triacylglycerol and
phospholipids. Pharmacological and molecular inhibition of LPA2, FAS or ACC

xvii

attenuated LPA-dependent cell proliferation, indicating that upregulation of lipid
synthesis is an integral component of the proliferative response to LPA. In further support
of this, downregulation of LPA2 expression led to dramatic inhibition of anchoragedependent and –independent growth of ovarian cancer cells.
To support increased biomass generation, rapidly proliferating cancer cells
enhance carbon influx by activating glycolysis. In the next part of the study, we
investigated if LPA signaling was also involved in activating aerobic glycolysis in cancer
cells. LPA indeed activated glycolysis in ovarian and other cancer cells but failed to elicit
this response in non-transformed cells, suggesting a cancer specific role of LPA in
regulation of glucose metabolism. While LPA had no effect on glucose uptake, we found
that LPA altered expression of multiple genes involved in glucose metabolism. The most
significant observation was that LPA treatment dramatically upregulated expression of
HK-2, one of the rate-limiting glycolytic enzymes. We explored the underlying
mechanism and found that LPA activates HK-2 transcription through LPA2-mediated
activation of SREBP-1. Two sterol regulator elements (SREs) on the human HK-2
promoter were identified to be responsible for LPA activation of the promoter. DNA
pulldown and chromatin immunoprecipitation assays confirmed that SREBP-1 bound to
these SREs in LPA-treated cells. Although in ovarian cancer cells, LPA treatment also
stabilized Hif-1α protein, an established activator of HK-2 and glycolysis, LPA-regulated
HK-2 expression and glycolysis was largely independent of Hif-1α. These results
established that LPA stimulates glycolysis via the LPA2-SREBP-HK-2 cascade in
neoplastic cells.

xviii

Taken together, this dissertation provides the first evidence for regulation of
cancer cell metabolism by LPA. The results indicate that LPA signaling is causally linked
to lipogenic and glycolytic phenotypes of cancer cells. Therefore, targeting the key LPA2
receptor could offer a novel and innovative approach to blocking tumor-specific
metabolism.
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CHAPTER 1
GENERAL INTRODUCTION

1.0 OVERVIEW
Ovarian cancer is the most lethal gynecological malignancy. It is estimated that in
the Unites States, 22,280 women will be diagnosed with ovarian cancer and 15,500 of
them will die of the disease in this year alone (1). Ovarian cancer is a heterogeneous
neoplastic group primarily originating from the ovarian surface epithelium. Based on the
microscopic morphologies, ovarian cancer can be classified as serous, endometrioid,
clear cell and mucinous subtypes (2). At Stage I, when the tumor is found only within the
ovary, or Stage II, when the tumor has spread only to pelvic organs, ovarian cancer is
highly curable, with an overall 5-year survival rate of greater than 80%. However,
ovarian cancer is usually diagnosed at advanced stages when malignant tumor cells have
spread to the abdomen (Stage III) or beyond the peritoneal cavity (Stage IV), where the
survival rate drops to 26.9%. The poor prognosis of ovarian cancer is primarily due to
lack of early detection and effective therapies for late stages of ovarian cancer. Thus it is
imperative to identify early markers for ovarian cancer in order to diagnose the disease at
curable stages.
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Less than 10% of ovarian cancers are linked to germline mutations of BRCA1
(breast cancer type 1 susceptibility protein) and BRCA2 genes (3). Most ovarian cancers
are sporadic, and like other epithelial cancers, are clonal in nature (4), accumulating
series of mutations during disease progression. Mutations in a number of tumor
suppressors and oncogenes have been implicated in ovarian cancer development and
progression. The tumor suppressor gene tumor protein 53 (TP53) has been found to be
mutated in 10-15% of low grade and 40-50% of high grade ovarian cancers (5) and its
expression is directly correlated with therapeutic responsiveness (6). Somatic mutations
in other tumor suppressors such as PTEN (Phosphatase and tensin homolog) and
BRCA1/2 have a low incidence. However, additional genes that have been suggested to
act as tumor suppressors exhibit reduced expression in ovarian cancer cancers by
epigenetic and other mechanisms (Table 1.1). Along with loss of tumor suppressor genes,
several oncogenes have also been found to be mutated, amplified or overexpressed in
ovarian cancers (Table 1.2). Thus based on the mutational profiling, ovarian cancers can
be divided into either low grade tumors, with mutations in KRAS (V-Ki-ras2 Kirsten rat
sarcoma viral oncogene homolog), BRAF (v-Raf murine sarcoma viral oncogene
homolog B1) and PIK3CA (phosphoinositide-3-kinase, catalytic, alpha polypeptide), and
LOH (loss of heterozygosity) on Xq, or high grade tumors with mutations in TP53,
BRCA1, BRCA2 and LOH on 7q and 9p (2,5).
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Table 1.1 Altered expressions of tumor suppressor genes in ovarian cancer
Gene

Percent alteration

TP53

10-50%

ARHI

60-75%

RASSF1A

50-70%

PEG3

75%

Mechanism of
altered expression
Mutation, loss of
function
Imprinting; LOH;
promoter
methylation
Promoter
methylation
LOH; promoter
methylation

Reference
(5)
(5,7,8)
(9,10)
(8,11)

Table 1.2 Altered expressions of oncogenes in ovarian cancer
Gene

Percent alteration

RAB25
MYC

54-89%
29%

EGFR

28-62%

ERBB2

8-11%

KRAS

30-52%

Mechanism of altered
expression
Overexpression
Overexpression
Overexpressed,activation
mutations
Overexpression,
activation mutation
Overexpression,
activation mutation

Reference
(12,13)
(14,15)

(16,17)
(18,19)

In addition to abnormal expression of oncogenes and tumor suppressor genes, a
variety of autocrine and paracrine growth factors influence ovarian cancer progression. A
prototype growth factor pathway involved in promotion of ovarian cancer progression is
the EGF-EGFR (Epidermal growth factor- Epidermal growth factor receptor) system (20).
Substantial evidence suggests that overexpression or mutations of EGFR is seen in a
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significant percentage of ovarian cancer 28-62% (21,22). HER2 (Human Epidermal
Growth Factor Receptor 2), another member of the EGFR family, is also abnormally
overexpressed (38-52%) or activated in ovarian cancers, resulting in more aggressive
tumor behavior and a poor prognosis (23,24). Recently, the anti-EGFR or HER2 small
inhibitors and antibodies have been used alone or in combination with chemotherapies for
treatment of a variety of solid tumors with significant improvement of patient survival,
confirming the importance of the EGFR family in maintaining cancer cell growth and
survival (25).
In contrast to these receptor tyrosine kinases (RTKs), the significance of Gprotein coupled receptor (GPCR), the largest family of cell surface receptors, in
regulation of cancer cells has not been as well appreciated, although numerous
publications suggest that many GPCR/ligand systems stimulate proliferation of normal
and neoplastic cells. The most important GPCR/ligand system in ovarian oncogenesis is
lysophosphatidic acid (LPA) and its GPCRs. Many ovarian cancers exhibit aberrant LPA
production, receptor expression or signal transduction (5). In spite of ample evidence for
LPA to promote proliferation, migration and invasion of ovarian tumor cells, the
molecular players involved in LPA-mediated regulation of these processes and ovarian
oncogenesis remains poorly understood. We have undertaken this study to test a novel
hypothesis

that

LPA is a pathophysiological

factor present

in

the tumor

microenvironment to drive hyperactive lipogenesis and glycolysis, which are hallmarks
of malignant cells. Our results presented in Chapter 1 and Chapter 2 indeed provide
strong evidence to support this previously unrecognized role of LPA in ovarian and other
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cancer cells. We have also gained evidence that LPA promotion of lipogenesis and
glycolysis is an integral component of the cellular proliferative program. Thus this thesis
study provides a link from LPA signaling to regulation of cellular metabolic processes,
proliferation and malignant phenotypes.
1.1 LYSOPHOSPHATIDIC ACID
LPA (1-acyl-2-hydroxy-sn-glycero-3-phosphate) is the simplest naturally
occurring phospholipid. It is comprised of a glycerol backbone with one phosphate group
at sn-3 position and a fatty acyl chain at either the sn-1 or sn-2 position. Fatty acyl chains
found in LPA are either saturated (C16:0, C18:0) or unsaturated (C18:1, C20:4) long
chain fatty acids which are linked to the glycerol backbone by acyl or alky linkages. LPA
is a component of serum, reaching concentrations of 1-5 μM (26), and is found attached
to albumin with a stoichiometry of 3 mole of LPA/mole of albumin (27). Binding with
albumin is necessary for LPA to elicit its activity and albumin-bound LPA is often
regarded as the heat stable and lysophospholipase sensitive component of serum’s
mitogenic activity (28,29). Apart from serum, LPA is also found in other body fluids
such as plasma, saliva, hair follicles and malignant effusions (30).
1.1.1 LPA METABOLISM
LPA production is an enzyme-catalyzed process and, depending on the site of
production, can be catalyzed by different cascades of enzymes. LPA is primarily
produced and secreted in extracellular fluids. However, LPA in small amounts can also
be produced intracellularly. LPA is an intermediate product of triacyl glyceride synthesis
5

and can be generated by glycerol-3-phosphate acyltransfeases (GPAT) in the
mitochondria and endoplasmic reticulum by acylation of glyceraldehyde-3-phosphate.
LPA produced by this route is rapidly converted to phosphatidic acid (PA) which serves
as the precursor for synthesis of other glycerol phospholipids (31). Till date there has
been no direct evidence that this intracellular pool of LPA is secreted out of the cell and
acts as a ligand of cell surface LPA receptors.
There are two major pathways that contribute to extracellular LPA production
depending on the starting substrate (Figure 1.1). One route is mediated by the action of
phospholipase A2 (PLA2) or phospholipase A1 (PLA1) on phospholipids, followed by
conversion of resulting lysophospholipids to LPA by lysophospholipase D (lysoPLD).
The identity of this mysterious lyso PLD enzyme remained elusive for a long time, even
though several observations suggested the presence of such an enzyme. Extended
incubation of rat plasma (32) or human follicular fluid (33) lead to generation of LPA
with a concomitant decrease of lysophosphocholine (LPC). Moreover, incubation of
fibroblasts with phospholipase D from Streptomyces chromofuscus lead to rapid release
of LPA and a reduction of LPC (34). These studies provided evidence for the presence of
a secreted enzyme that could use LPC either in circulation or from the outer leaflet of cell
membranes as its substrate to generate LPA. This enzyme was later discovered as
autotaxin

(ATX)

(35),

an

eco-enzyme

of

the

nucleotide

pyrophosphatase/

phosphodiesterase (NPP) family. This route involving ATX is generally believed to be
the primary source of LPA production in cancer and by activated platelets in blood
circulation (36). Subsequently, mice heterozygous for ATX have been shown to have 50%
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less LPA plasma levels as compared to their wild type counterparts, suggesting the
importance of ATX in physiological production of LPA (37). ATX is an enigmatic
enzyme which is known for its role in tumor invasion, neovascularization and metastasis
(38-40). The crystal structure of ATX has recently been determined which offers new
understanding about the substrate recognition and its mechanism of action. ATX has
multiple domains, one of which is an atypical phosphodiesterase catalytic domain that is
responsible for LPA production, while two N-terminal somatomedin B (SMB) like
domains and the C-terminal nuclease-like (NUC) domain aid in substrate specificity and
presentation (41,42). Moreover, it was also suggested that ATX could attach itself to β3integrins and deliver LPA directly to its receptors via a hydrophobic channel (42). It
could be thus speculated that the actual concentrations of LPA around the tumor cells
could be more than the serum or plasma LPA levels in cancer patients.
The second less studied route of LPA generation is by the action of
monoacylglycerol kinase (MAG-kinase) on monoacylglycerol (43), this pathway has also
been suggested to be active in cancer cells (44).

Figure 1.1 Two major routes for LPA production.
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The effective concentration of LPA is regulated both by its production and by its
degradation. The important players in the degradation processes are lipid phosphate
phosphatases (LPPs). Three different isoforms of LPPs (LPP-1, LPP-2 and LPP-3) have
been identified to date which are capable of dephosphorylating LPA, PA, sphingosine-1phosphate (S1P), ceramide-1-phosphate and diacylglycerol pyrrophospate (DGPP)
(45,46). Several publications have, shown LPP-1 to specifically inactivate LPA in vitro
and in vivo (46-48) . These LPPs are membrane associated enzymes with their catalytic
domain facing the extracellular environments and as their name suggests, they cleave off
the phosphate group from LPA, generating monoacyl glycerol (MAG). Another
mechanism for reducing LPA concentrations is by converting LPA to PA by the acylation
reaction carried out by LPA acyl transferases (LPAAT) (49,50).
1.1.2 LPA RECEPTORS
LPA has numerous biological functions in physiological and pathophysiological
conditions (reviewed in Table 1.3). These effects of LPA are mediated by signaling
through its membrane-associated GPCRs. Seven LPA receptors have been identified to
date. The expression patterns of these receptors vary in their relative amounts and from
one tissue to another, thereby leading to a complex regulation of cellular processes by
LPA in a tissue dependent manner. In cancer, LPA signaling is heightened due to
increased levels of ligand (LPA) or receptor expression, influencing processes such as
cancer cell proliferation, survival, migration, and invasion. LPA receptors fall into two
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sub-groups, the endothelial differentiation gene (Edg) family of LPA receptors and nonEdg LPA receptors.

Table 1.3 Physiological and pathophysiological effects of LPA
Effect
Cell proliferation and survival
Cell migration and invasion
Tumor progression
Wound healing in vivo
Cell contraction
Platelet activation and
aggregation
Cytokine production
Stabilization of embryonic vessels
Neurite retraction,
collapse/turning of growth cones
Inhibition/reversal of
differentiation
Cerebral cortex growth and
folding ex vivo
Initiation of neuropathic pain and
demyelination of the dorsal
root in vivo
Demyelination of the dorsal
root ex vivo
Membrane depolarization
(chloride efflux-mediated)
Blastocyst implantation (timing
and spacing)

Cell type/remarks
Many cell types, normal and transformed (51)
Many cell types, normal and transformed (51)
Mouse xenografts (overexpression or knockdown
of LPA receptors) (51,52)
Skin (53); intestinal epithelium (54)
Smooth muscle cells; myofibroblasts (55)
LPA in atherosclerotic plaques; synergy with ADP
(56,57)
Fibroblasts; astrocytes; leukocytes; epithelial and
endothelial cells; carcinoma cells (51)
Mouse allantois explant culture (58)
Neuroblastoma cells (28); primary neurons (59)
Neuroblastoma and glioma cells (60); astrocytes
(61) vascular smooth muscle cells (62); preadipocytes (63)
Action on neural progenitor cells; not observed in
LPA1/LPA2-deficient mice (64)
Reduced in LPA1-deficient mice (65)
Direct action on myelinating Schwann cells (66)
Neuronal cells (67); fibroblasts (68)
LPA3-mediated (69)
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The Edg LPA receptors (LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7) have been
extensively studied. They are structurally similar with 46-50% amino acid homology
between

them

(70).

However

the

non-Edg

subgroup

of

LPA

receptors

(LPA4/GPR23/P2Y9, LPA5/GPR92 and LPA6/P2Y5) are phylogenetically distinct with
less than 15% sequence homology among the family members (70) (Figure 1.2).

LPA /GPR87
7

Figure 1.2 A phylogenetic tree of human GPCRs, depicting the phylogenetic
difference between Edg and non-Edg GPCR receptors of LPA. (Adapted from
Yanagida, K., and Ishii, S. (2011) Non-Edg family LPA receptors: the cutting
edge of LPA research. J Biochem 150, 223-232).
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LPA1/Edg2 was the first LPA receptor to be identified. In an effort to identify
GPCRs regulating cortical neurogenesis, Chun and colleagues identified a GPCR
expressed in the cortical neurogenic region and named it ventricular zone gene-1 (VZG1). They overexpressed this gene in neuronal cells and observed cell rounding and adenyl
cyclase inhibition specifically in response to LPA among other ligands including lipids
(71), providing evidence for identification of the first LPA receptor. LPA1 in humans is
expressed in a variety of adult tissues including heart, small intestine, pancreas, kidney,
prostate, ovary, and testis, but the highest expression of LPA1 had been observed in the
mouse brain (70,71). Hence the role of LPA1 in the developing nervous system is a major
focus of research. LPA1 has been shown to be important for neurogenesis in the dentate
gyrus, synapse formation in the hippocampus and for overall cortical development (7274). The importance of LPA1 was evident from studies using LPA1 knockout mice which
had a semi lethal phenotype (50% neonatal deaths). Among the mice that survived, some
displayed craniofacial deformities, frontal hemorrhages and defects in suckling behavior
(75). By subjecting the LPA1 knockout mice to pathophysiological conditions, its roles in
initiation of neuropathic pain (65), and in pulmonary and renal fibrosis have been
established (76,77).
LPA2/Edg4 was identified from GenBank searches of orphan GPCRs and its high
amino acid sequence similarity to LPA1 (55%) (78). In humans, LPA2 gene is located on
chromosome 19 and encodes for a 39 kd protein (79). The expression of LPA2 as
compared to LPA1 is relatively restricted. In adult mice, LPA2 is expressed in lung,
spleen, stomach, testis and kidney (80), and in humans, its expression has been detected
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in pancreas, thymus, testis, spleen and leukocytes (81). LPA2 knockout mice are viable,
grossly normal and display no apparent breeding abnormality. Moreover the LPA1 and
LPA2 double knockout mice did not show any phenotype additional to LPA1 knockout
mice, except for a minor increase in frontal hematomas (82). Thus it can be speculated
that under physiological conditions, LPA2 may not play a significant role and its
functions might be redundant to LPA1. However, LPA2 has been found to be upregulated
in various cancers and may contribute to pathogenesis of ovarian cancer, colorectal
cancer and other malignancies (83,84).
LPA3/Edg7 was initially identified as an orphan receptor using degenerate PCRbased cloning. Based on its responsiveness to LPA and its homology to LPA1-2 receptors
(53.7 and 48.8% for LPA1 and LPA2 respectively), it was identified as the third Edg LPA
receptor (85,86). The LPA3 gene is located on chromosome 1 and encodes for a 40 kd
protein. In human, LPA3 expression is detectable in a number of tissues including heart,
testis, prostate, pancreas, lung, ovary, and brain (85,86). In mice, LPA3 is highly
expressed in the uterus, and during post pregnancy almost exclusively in the luminal
endometrial epithelium (69,70). Its expression has also been shown to be regulated by
progesterone and estrogen (87). In accordance to its expression and potential hormonemediated regulation, LPA3 female knockout mice had a dramatic phenotype in the
reproductive system. Loss of LPA3 resulted in delayed implantation and an alteration in
embryo spacing resulting in reduced litter size (69). It is, however, notable that LPA3
knockout mice had no observable phenotype in the nervous system, in spite of its
expression in brain.
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LPA4/GPR23/P2Y9 was the first non-Edg family LPA receptor to be identified.
As part of their “de-orphaning” project, Noguchi et al. identified GPR23/P2Y9, a
receptor of the purinergic sub-family of GPCRs as the fourth LPA receptor (88). Human
LPA4 is expressed in a variety of tissues, with highest expression observed in the ovary
(88). It is located on the X chromosome and encodes a 42 kd protein. We were the first
group to generate and characterize LPA4 knockout mice. The LPA4 null mice were viable
and had no phenotypic abnormality. However, we demonstrated that the loss of LPA4
sensitizes mouse embryonic fibroblasts (MEFs) to LPA-induced migration and tumor cell
invasion (89), a process involving the inhibition of LPA1 receptor activity. This study
was the first evidence for functional antagonism between LPA receptors. Following our
study, Sumida et al also generated LPA4 knockout mice and reported partial lethality and
defects in blood vessel formation in their LPA4 knockout mice (90). Although we did not
observe any phenotypic defects in our LPA4 null mice, the difference in phenotype could
arise from difference in genetic backgrounds of mice used.
LPA5/GPR97 is a recently identified LPA receptor that shares 35% homology
with LPA4 and is structurally distant from the Edg LPA receptors (91). The LPA5 gene is
located on chromosome 12 and codes for a 41 kd protein. Using mouse and human tissue
samples, LPA5 has been shown to be expressed in small intestine, colon, stomach, spleen,
heart and embryonic brain, with highest expression observed in the small intestine of
mice and spleen of humans (91,92). Very few studies have been carried out on LPA5, but
it has been suggested to play a role in platelet activation (93) and cyclooxygenase (Cox-2)
induction in some ovarian cancer cell lines (94).

13

The LPA6/P2Y5 gene is located on chromosome 13 at a locus (q14.11-13q21.33)
and is linked to an autosomal recessive form of hypotrichosis, which lead to its discovery
(95). Pasternack et al. has subsequently shown that LPA6 is the expressed in the hair
follicle and is required to maintain hair growth (95).
LPA7/GPR87 is the last known LPA receptor. The LPA7 gene is present on
chromosome 3 in both mouse and humans. It has been shown that LPA7 is expressed in
placenta, ovary, testis, prostate, brain, and skeletal muscles in mice (96). Other GPCRs
such as P2Y10 (97) and GPR35 (97) have been proposed as additional LPA receptors but
they have not been validated by independent studies.
1.1.3 LPA RECEPTORS AND CANCER
LPA is known for its proliferative and migratory effects on a variety of cell types,
and since LPA levels are elevated in cancer patients, LPA signaling is known to be
heightened in cancer cells as well. LPA receptors are upregulated in a number of cancer
types, thereby contributing to elevated LPA signaling in cancer.
Although LPA1 is expressed in a wide range of human and mouse tissues, analysis
of LPA1 mRNA expression data from tumor samples failed to conclusively prove
overexpression of this receptor in major cancers (98). Moreover several groups have
suggested LPA1 to be downregulated in cancers of the ovary, colon, vulva, thyroid, and
testis compared with corresponding normal tissues (99-101). Irrespective of its
expression changes in cancer, there is strong evidence that LPA1 is involved in oncogenic
processes, especially in promotion of tumor cell invasion and metastasis. Overexpression
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of LPA1 in cell lines where LPA receptors are either absent or had very low expression
(B103, Rh7777 and SkBr3), resulted in increased proliferative and migratory responses to
LPA and increased metastasis to the bone when injected into nude mice (56,102,103).
The role of LPA1 in enhancing migratory and metastatic potential of cancer cells was also
supported by the observation that, Nm23-H1 (a metastatic suppressor) inhibited
expression of LPA 1 (104,105).
Unlike LPA 1 , expression of LPA 2 is known to be upregulated in a variety
of cancers and is generally believed to be the major LPA receptor contributing to
carcinogenesis. Our lab was the first to report overexpression of this reporter in
ovarian cancer lines and primary ovarian cancer (106,107), following which
several groups have identified overexpression of this receptor in other cancer
types including breast (108), gastric (109), colorectal (110), and thyroid cancers
(111). There are several lines of evidence that support a role of LPA 2 in driving
tumorigenesis. Overexpression of LPA 2 in ovarian cancer cell lines increased
production of oncogenic factors such as interleukin-6 (IL-6), interleukin-8 (IL-8),
and vascular endothelial growth factor (VEGF), leading to an increased tumor
burden in mice when these cells were injected subcutaneously (83). Breast tissue
specific expression of LPA 2 (driven by the MMTV promoter) in mice was found
to increase the incidence of mammary tumors, as compared to wild type litter
mates. Moreover, LPA 2 knockout mice were found to be resistant to intestinal
tumor formation in both the Adenomatous polyposis coli (APC) +/- mouse model
(112) and dextran sulfate sodium model (113). It is thus evident that LPA 2 plays a
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major role in tumor development. However, the exact mechanism by which LPA 2
regulates oncogenic processes remains elusive.
The role of LPA 3 in cancer is not fully understood. It has been found to be
overexpressed in ovarian (107) and prostate (114) cancers but downregulated in
some breast cancers (101). However in ovarian cancer, LPA 3 has been found to
contribute to tumorigenicity (83). In other cancers such as colon cancers, there
are conflicting reports. Although it is downregulated in colon cancer (99), there
is experimental evidence that LPA 3 contributes to LPA-driven proliferation of
these cells (115). In addition, LPA 3 negatively regulates LPA 1 -driven migration
of rat lung cancer cells (116). It is evident that further studies are required in
order to clarify the role of LPA 3 in cancer.
As compared to the Edg LPA receptors, the contributions of non-Edg receptors in
tumorigenesis have not been elaborately studied. LPA4, the first non-Edg family receptor
to be identified, is expressed at low levels as compared to other LPA receptors or is
undetectable in a majority of cancer cell lines. Analysis of expression data from some
cancer studies failed to provide any significant difference in LPA4 levels between cancers
and their corresponding non cancer tissues (Figure 1.3). Thus it is imperative to study
LPA4 expression in individual cancer types separately. We have recently shown that
LPA4 expression levels are reduced after Ras transformation, suggesting that reduced
expression of this receptor is one of the molecular changes associated with oncogenic
transformation (117).
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Roles of LPA5, LPA6 and LPA7 in cancer have not been adequately studied.
However, expression analysis suggests their expression could be deregulated in cancer
(Figure 1.3).
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1. Lung (30)
2. Lung Adenocarcinoma (27)

1. Breast (9)
2. Invasive Ductal Breast Carcinoma
(33)

1. Ovary (4)
2. Ovarian Serous Adenocarcinoma
(41)

1. Bladder (48)
2. Superficial Bladder Cancer (28)

1. Colon (10)
2. Colon Carcinoma (5)

Figure 1.3 Expression of LPA receptors in cancer. Expression patterns of LPA
receptors are depicted as normal vs. tumor of their log2 median-centered intensity. The
Oncomine™ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and
visualization.
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1.1.4 LPA RECETOR MEDIATED SIGNALING
Like other GPCRs, LPA receptors couple to multiple G-proteins. G-proteins are
hetrotrimeric proteins (composed of α-, β- and γ- subunits) that transduce signals from
the receptors to various effectors. In the inactive state, G-proteins remain attached to
GDP (guanosine diphosphate); on activation, the GDP gets replaced by GTP (guanosine
triphosphate) resulting in release of the α-subunit from βγ-subunits. These subunits then
go on to activate various signaling pathways. As shown in Figure 1.4, LPA receptors are
majorly known to couple to Gαi, Gαq, Gα12/13 and in certain cases Gαs. LPA1 and LPA2
receptors couple to Gαi, Gαq, and Gα12/13, whereas LPA3 couples to Gαi and Gαq. The nonEdg LPA receptors are not known to activate Gαi but are known to activate Gαs instead.
This is a significant difference as coupling to Gαs leads to activation of adenly cyclase
(AC) and hence leads to increase in cAMP (cyclic-adenosine monophosphate), whereas
as Gαi mediates inhibition of AC. LPA via Gαi inhibits cAMP accumulation, activates
Ras-MAPK (mitogen-activated protein kinase) pathways, Rac GTPases via TIAM1 (a
GDP/GTP exchange factor) and the PI3K-AKT pathway (102,118-121). LPA mediated
activation of Gαq is linked to activation of phospholipase C (PLC), which catalyzes
hydrolysis of phosphoinositol biphosphate (PIP2) to diacylglycerol (DAG) and inositol
triphosphate (IP3) with subsequent release of intracellular calcium and activation of
PKCs (protein kinase C) (118). LPA via Gα12/13 activates RhoA leading to cytoskeletal
changes and cell rounding (122). Thus LPA via Gαi regulates cell proliferation and
survival, via Gαq regulates the production of secondary messengers and by combined
actions of Gαi and Gα12/13 regulates cell migration and invasion.
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Apart from the Gα- subunit, Gβγ-subunits have also been shown to activate
signaling pathways. Upon LPA stimulation, Gβγ-subunit has been shown to associate
with Rab11a-containing early and late endosomes, leading to recruitment and activation
of the PI3K-AKT pathway (123).

Figure 1.4 LPA receptor mediated signaling

1.1.5 LPA AND CELL PROLIFERATION
The mitogenic effect of LPA was first discovered in fibroblasts (118);
subsequently, LPA has been found to increase cellular proliferation in cells of multiple
lineages including transformed cells. The proliferative effect of LPA is generally
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regarded to be driven by the pertussis toxin (PTX) sensitive Gαi pathway (118,120),
however possible contribution by RhoA signaling has also been suggested (124).
Although LPA activates the Gαq-PLC pathway, this pathway is not required for
proliferation (118). Downstream of Gαi, the Ras-MAPK and the PI3K-AKT pathways
have been known to mediate LPA-induced cell proliferation (120,125). These pathways
are also involved in promotion of cell survival (126,127).
All Edg receptors coupled to Gαi are capable of enhancing cell proliferation when
analyzed individually in ovarian cancer cell lines (83). However, Edg LPA receptors are
often found to be co-expressed, making it difficult to link a biological response to a
specific receptor. The crosstalk among the Edg LPA receptors likely plays an important
role in the proliferative response to LPA. Studies using mouse embryonic fibroblasts
have showed that LPA1 and LPA2 have redundant functions in terms of cellular
proliferation. Loss of both receptors caused a dramatic inhibition of LPA-dependent cell
proliferation (82). In transformed cells, there is emerging evidence that implicates LPA2
in driving cell proliferation and tumorigenesis. LPA2 has been shown to activate a
number of cell cycle regulators and oncogenic proteins including IL-6, VEGF, HIF1α, cMyc, cyclin D1, kruppel-like factor 5, and Cox-2 (112,113,128-131). These protein
factors could be important mediators of LPA2’s biological functions. LPA is known to
transactivate epidermal growth factor receptor (EGFR), platelet derived growth factor
receptor (PDGFR) and hepatocyte growth factor receptor (c-Met). A signal input from
these receptor tyrosine kinases seems to be required for maximum induction of
proliferation by LPA in various cellular contexts (132-134).
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1.2 CANCER CELL METABOLISM
Cell metabolism refers to complex biochemical reactions within a cell that use
nutrients as substrates to generate macromolecules (such as protein, DNA and lipids) and
energy (Adenosine-5’-triphosphate, ATP). ATP inside a cell is generated by glycolysis,
fatty acid β-oxidation and the tricarboxylic acid cycle (TCA). During glycolysis, glucose
is converted into pyruvate with the net output of 2 ATP molecules, and in the absence of
oxygen, lactate becomes the end product. However, if oxygen is in abundance, pyruvate
enters the TCA cycle and subsequently a total of 36 molecules of ATP can be generated
from complete catabolism of one glucose molecule. These processes are tightly
coordinated and anabolic or catabolic processes are activated to meet the cellular
requirements. Cancer cells have evolved an altered metabolic profile that is well suited
for an increased rate of cellular proliferation.
The first evidence of an altered metabolic program in cancer cells was provided
by Otto Warburg in 1920s. He showed that transformed cells continue to use glycolysis
even in the presence of oxygen as the major ATP generation process, which later came to
be known as the Warburg effect (135). This observation has been demonstrated in a
variety of cancers and has been exploited in the detection of cancer by
fluorodeoxyglucose positron emission tomography (FDG-PET). The Warburg effect
initially provided a paradox as cancer cells by definition are rapidly proliferating cells
and preferential use of glycolysis would generate less ATP per molecule of glucose.
However, recent observations suggests that cancer cells utilize glycolysis to preferentially
increase carbon flux inside the cells which is required to generate biomass needed to meet
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the demand for rapid cellular proliferation. Thus cancer cells are characterized by an
increased rate of glycolysis, highly active DNA and protein synthesis and hyperactive de
novo lipogenesis.
1.2.1 DE NOVO LIPOGENEIS
Fatty acids are important constituents of cell membranes, signaling molecules,
and secondary messengers. There are two sources of fatty acids for cellular metabolism, 1)
external fatty acids obtained from diet and 2) endogenously synthesized fatty acids. The
majority of cells in humans rely on dietary fats to meet their requirements and hence the
inherent process of fatty acid synthesis (de novo lipogenesis) is generally inhibited. In
contrast, cancer cells heavily depend on fatty acids from de novo synthesis. Using radio
isotopes, it has been showed that more than 90% of fatty acids are generated by cancer
cells themselves and only a minor fraction is contributed by cellular uptake of
extracellular fatty acids (136). Fatty acid synthesis is carried out in the cytosol from
acetyl CoA which acts as the carbon donor (Figure 1.5). The first step in fatty acid
synthesis is the generation of malonyl CoA by carboxylation of acetyl CoA, which is
carried out by acetyl CoA carboxylase (ACC). Sequential addition of 2 carbon unit leads
to the generation of long chain fatty acids, catalyzed by a multi-functional protein known
as fatty acid synthase (FAS).
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Figure 1.5 An illustration of fatty acid synthesis

1.2.2 KEY MEDIATORS OF LIPOGENESIS IN CANCER
Generation of fatty acids in the cytosol depends on the ability of cells to generate
cytosolic acetyl CoA catalyzed by ATP citrate lyase (ACL), as acetyl CoA generated in
the mitochondria cannot be directly transported to the cytoplasm. The acetyl CoA thus
produced feeds into fatty acid synthesis, cholesterol synthesis and in acetylation reactions,
suggesting the importance of this enzyme in multiple processes. In humans, ACL has
been found to be abundantly expressed in liver and adipose tissues (137,138) and is often
seen upregulated in lung, prostate, bladder, breast, liver, stomach, and colon tumors (139145). The importance of ACL in de novo lipogenesis and proliferation of cancer cells is
suggested by the observation that pharmacological and RNA interference (RNAi)
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mediated inhibition of ACL leads to reduced cell growth, survival and tumorigenesis of
cancer cells (146,147).
The second enzyme in fatty acid synthesis is ACC. It catalyzes the first committed
step in fatty acid synthesis. Mammalian ACC consists of multi-functional domains (biotin
carboxylase, biotin carboxyl carrier, and carboxyltransferase). ACC has two isoforms,
ACC1 and ACC2; the former is the predominant one present in lipogenic tissues (liver,
adipose tissue, lactating mammary glands) and cancer cells, and the latter is expressed in
skeletal muscle, heart and liver (148). ACC1 has been shown to be upregulated in cancer
of prostate, breast and liver (141,149,150). Interestingly, pre-neoplastic lesions with
increased expression of ACC1 have been shown to have a higher chance of developing
into breast cancers (150). Knockdown of ACC1 in cancer cells results in reduced
proliferation and viability (151,152).
In 1994, Kuhajda and colleagues identified the oncogenic antigen-519 (OA-519)
as FAS (153), and several subsequent studies showed OA-519 overexpression to correlate
with poor patient outcomes (154). FAS has been shown to be upregulated in cancers of
breast, colorectum, prostate, bladder, ovary, esophagus, stomach, lung, oral tongue, oral
cavity, head and neck, thyroid and endometrium (154-156). There are two possible
mechanisms by which FAS can be upregulated in cancer. The first involves the activity
of growth factor receptors. In particular, the EGF family receptors ERBB1 and ERBB2
have been shown to regulate FAS transcriptionally (157-159), via PI3K or MAPK
pathways (160-162). The second route is via a post-translational mechanism, supported
by the observation that in prostate cancer cells FAS has been found to interact with
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ubiquitin specific proteases USP2a. USP2a protected FAS from ubiquitin-mediated
degradation, and knockdown of USP2a reduced FAS levels (163). Correlation between
FAS and USP2a expression can also be seen in microarray analyses (164). It should be
noted that to date such regulation of FAS has not been reported in any type of cancer
cells.
1.2.3 REGULATION OF LIPOGENESIS IN CANCER
The lipogenic process in cancer cells shares certain similarities with nontransformed cells (liver and adipose tissue). In both cases, FAS expression is regulated by
sterol regulatory element binding proteins (SREBPs). The SREBP family of transcription
factors comprises three members SREBP-1a, SREBP-1c, and SREBP-2 (165,166).
SREBP-1a and SREBP-1c are produced from one gene by the use of alternative
promoters (166-168), and SREBP-2 is a product of another gene with no known other
isoforms (169). Each SREBP has three domains: 1) a N-terminal transactivation domain,
2) a hydrophobic transmembrane region, and 3) a C-terminal regulatory domain (170).
Although SREBPs have similar consensus DNA binding sites, there seems to be some
specificity in transactivation of target genes. Studies using liver specific expression of
SREBPs in mice have suggested that SREBP-1a and SREBP-1c regulate genes involved
in fatty acid synthesis (171,172), while SREBP-2 regulates multiple genes in cholesterol
synthesis (173).
SREBPs can be regulated by three possible mechanisms 1) transcriptional, 2)
proteolytic cleavage of SREBP precursors, and (3) post-translational modification of
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nuclear SREBPs. Studies involving fasting/refeeding regimes in rodents showed that
changes in nutritional status regulated the expression of SREBP-1c in liver, white adipose
tissue and skeletal muscles (174-177). The expression of SREBP-1c was found to be
reduced during starvation and increased when fed carbohydrate rich diets. Consistent
with these observations, insulin and glucagon were found to be the upstream modulators
of the increase or decrease in SREBP-1c transcription respectively (172,178). SREBP-1c
has also been shown to be regulated by activation of androgens (179), progesterone (180)
and the nuclear hormone receptor LXRα (181). SREBP-1a and SREBP-2 also are
regulated to a minor extent by transcriptional mechanisms, and under reduced sterol
concentrations both proteins can be transcriptionally upregulated (170).
Proteolytic cleavage of SREBP is a highly complicated process as depicted in
Figure 1.6. Following translation; SREBPs are localized to the endoplasmic reticulum
(ER). When cholesterol and 25-hydroxycholesterol are present in adequate amounts,
SREBPs forms a complex with sterol regulatory element binding protein cleavage
activating protein (SCAP) and insulin-induced gene (INSIG) proteins (182,183). A fall in
intracellular cholesterol levels leads to disruption of the complex, unmasking the sorting
signal in SCAP. The SCAP-SREBP complex is then transported to the Golgi via COPIImediated vesicular transport (182). In the Golgi, two proteases, site 1 protease (S1P)
(184,185) and site 2 protease (S2P) (186), sequentially cleave the precursor forms of
SREBPs thereby releasing the active N-termini, which translocates to the nucleus to bind
and activate their target genes .
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Inside the nucleus, the transcriptional activity of SREBPs is regulated by covalent
modifications or by interactions with other proteins. Studies in cell lines suggest that
insulin via the MAPK pathway leads to phosphorylation of SREBPs at several sites,
which have been shown to increases transactivation capacities of SREBPs (187,188). In
addition to MAPK, mammalian target of rapamycin (mTOR) has been recently found to
influence the transcriptional activity of SREBPs (189). mTORC1 phosphorylates Lipin1
and prevents its nuclear entry. Since nuclear Lipin1 decreases transcriptional activities of
both SREBP-1 and SREBP-2, activated mTOR enhances the transactivation potential of
SREBP proteins. Reduced activities of SREBPs have also reported to be caused by
sumoylation (190) and by degradation via an ubiquitin-proteasome pathway (191).

Figure 1.6 Proteolytic activation of SREBP.
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1.2.4 AEROBIC GLYCOLYSIS
Glycolysis is a biochemical process that converts glucose to pyruvate, generating
2 molecules of ATP per molecule of glucose. The steps of the process and the enzymes
involved are depicted in Figure 1.7. All living cells need energy (ATP) to maintain
cellular homeostasis. Transformed cells, however, have increased requirements for
energy and intracellular nutrients to carry on non-spontaneous anabolic reactions that
support heightened cell growth. It is thus believed that to satisfy the above requirements,
cancer cells have undergone a shift to aerobic glycolysis. Aerobic glycolysis generates
less ATP but leads to increased carbon flux (as nutrients) in the cell, so to make up for
the inefficiency in ATP generation, cancer cells have a heightened rate of glucose uptake.
Hence by selection of glycolysis over oxidative phosphorylation, cancer cells have been
able to maintain a balance between ATP generation and biomass production. It is
interesting to note that some unicellular organisms also prefer glycolysis. For example,
when fermentative yeast Saccharomyces cerevisiae was grown in media where glucose is
not the primary source of carbon, oxidative phosphorylation was preferred, but when
glucose was added, they rapidly shifted to the glycolytic pathway and this change
resulted in a faster growth rate (192,193). However, the same is not true for aerobic yeast
Yarrowia lipolytica or for aerobic bacteria Escherichia coli (194,195).

29

Figure 1.7 Enzymes involved in the glycolytic process.
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Thus it can be said that increased glucose uptake for glycolytic ATP generation or
anabolic reactions offers the following advantages to facilitate tumor cell growth:
1)

Intermediates of the glycolytic pathway can be used for anabolic reactions thus
branching into different pathways. For example glucose 6-phosphate can
contribute to ribose 5-phosphate synthesis. Dihydroxyacetone phosphate can lead
to triacylglyceride and phospholipid synthesis. 3-phosphoglycerate can contribute
to cysteine, glycine, and serine synthesis and pyruvate can generate alanine and
malate (193).

2)

Lactate is the principle end product of glycolysis secreted outside the cell, which
leads to acidification of the tumor microenvironments. This acidification aids in
tumor cell invasion (196) and immune modulation (197) facilitating tumor growth.

3)

A part of the glucose can be diverted to the pentose phosphate pathway (PPP),
generating NADPH which is required for fatty acid synthesis.

4)

Reliance on glycolysis could provide cancer cells with a survival advantage under
reduced oxygen concentrations, which would be fatal for cells relying on
oxidative phosphorylation (198).

1.2.5 KEY REGULATORS OF GLYCOLYSIS IN CANCERS
Several studies suggest that control over glycolytic flux primarily resides at the
glucose transport and phosphorylation steps of glycolysis (199-201) and thus the key
players regulating glycolysis in cancer are glucose transporter 1 (GLUT1), hexokinase 2
(HK-2) and pyruvate kinase muscle isozyme (PKM2).
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GLUT1 is the most widely expressed, high affinity glucose transporter and has
been reported to be upregulated in various malignancies (202-208). Abnormal expression
of GLUT1 occurs early during tumorigenesis and RAS or SRC mediated cell
transformation is associated with GLUT1 upregulation (209). In addition, GLUT1
overexpression is linked to poor prognosis of cancer (208,210).
HK-2 catalyzes the irreversible first step of glycolysis, converting glucose to
glucose-6-phosphate. This is an important step as phosphorylation prevents exit of
glucose from the cell. There are four different isoforms of hexokinases. HK-2 and to a
lesser extent HK1 are the only enzymes that have been typically associated with cancer.
The switch from HK4 expressed in liver to HK-2 in cancer cells is one of the earliest
adaptations observed during tumorigenesis (211-213). Upregulation of HK-2 is seen in a
variety of cancers and consequently inhibition of HK-2 is often regarded as a possible
therapy against cancer (214,215). HK-2 is localized to the outer membrane of
mitochondria and is thought to be attached to the voltage-dependent anion channel
(VDAC) (216). This interaction between HK-2 and VDAC not only ensures an efficient
supply of ATP to HK-2 but is also critical for prevention of apoptosis (217,218). Thus
HK-2 regulates both cell proliferation and survival (219).
Pyruvate kinase (PK) regulates the conversion of phosphoenolpyruvate (PEP) to
pyruvate. There are four types of PK. Type l is found in the liver and kidneys, type R in
erythrocytes, type M1 in muscle and brain, and type M2 in self-renewing cells such as
embryonic and adult stem cells and cancer cells (220,221). While PKM1 is known for its
high activity and rapid generation of ATP, PKM2 in cancers has lower activity and
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reduces the amount of ATP generated by glycolysis (222,223). A recent study by
Christofk et al. showed that PKM2 provides an alternative path for the transfer of a
phosphate group, transferring it to PGAM1 (Phosphoglyceric acid mutase 1) instead of
ADP (Adenosine diphosphate) (224), providing explanation for the loss of ATP. This
mechanism thus uncouples ATP generation from glycolysis, thereby allowing glycolytic
intermediates to accumulate and enter other subsidiary pathways, including the
hexosamine pathway, uridinediphosphate (UDP)–glucose synthesis, glycerol synthesis
and the hexose monophosphate shunt.
1.2.6 REGULATION OF GLYCOLYSIS IN CANCER CELLS: CURRENT
UNDERSTANDING
Cancers cells are known to change their surrounding environment to better suit
their needs. As tumor mass increases, accessibility of tumor cells to oxygen reduces,
leading to a hypoxic state which has a dramatic effect on metabolism. Hypoxia leads to
stabilization of hypoxia inducible factor -1 (Hif-1) proteins, which regulate almost all
genes of the glycolytic pathway (225). Hif-1 is heterodimeric transcription factor
composed of α and β subunits; the β-subunit is constitutively expressed but the α-subunit
is regulated by the levels of oxygen (226,227). Under normoxic conditions, Hif-1α gets
hydroxylated by prolyl hydroxylase domain protein 2 (PHD2) on proline residue 402
and/or 564, and this modification leads to binding of the von Hippel–Lindau tumor
suppressor protein (VHL). VHL recruits an E3 ubiquitin ligase that degrades Hif-1α.
Under hypoxic conditions, the proline hydroxylation is inhibited, leading to accumulation
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of Hif-1α protein, which then binds to Hif-1β and activates transcription of its target
genes (225,228). In addition to stabilization under hypoxic conditions, under normoxic
conditions Hif-1α may be stabilized by mutations in tumor suppressor proteins such as
VHL (229,230), succinate dehydrogenase (SDH) (231) and fumarate hydratase (FH)
(232). Hif-1α, once present in sufficient amounts, will transactivate glucose transporters
(GLUT1, GLUT3) and enzymes contributing to increased glycolytic phenotype (HKI,
HKII, PFK-L, ALD-A, ALD-C, PGK1, ENO-alpha, PYK-M2, LDH-A, PFKFB-3) (233).
In addition to the tumor microenvironment, oncogenes, tumor suppressor genes
and their associated signaling pathways also play an important role in regulation of
aerobic glycolysis. Activated PI3K and Ras pathways have been shown to activate
glycolysis via regulating expression of various glycolytic genes (234). AKT, the
downstream effector of PI3K, enhances the rate of glycolysis by multiple mechanisms
including increased expression and membrane translocation of glucose transporters and
by

phosphorylating

key

glycolytic

enzymes,

such

as

hexokinase

and

phosphofructokinase-1(235,236).
Another oncogene with wide-ranging effects on glycolytic enzymes is c-Myc. It
has been shown that c-Myc coordinately regulates genes such as HK-2 and pyruvate
dehydrogenase kinase 1, along with Hif-1α (237). In addition to oncogenes, tumor
suppressor genes such as TP53 have been shown to upregulate expression of TIGAR
(TP53-induced glycolysis and apoptosis regulator), which as its name suggested, prevents
glycolysis by decreasing levels of fructose-2, 6-bisphosphate, an allosteric regulator of
phosphofructokinase-1. Thus, loss of TP53 in tumor cells leads to increased glycolysis.
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CHAPTER 2

LYSOPHOSPHATIDIC ACID ACTIVATES LIPOGENIC PATHWAYS AND DE
NOVO LIPID SYNTHESIS IN OVARIAN CANCER CELLS

Part of the work presented in this Chapter has been published in Journal of Biological
Chemistry J Biol Chem. 2012 Jun 3. [Epub ahead of print]

2.0 ABSTRACT
One of the most common molecular changes in cancer is the increased
endogenous lipid synthesis, mediated primarily by overexpression and/or hyperactivity of
fatty acid synthase (FAS) and acetyl-CoA carboxylase (ACC). The changes in these key
lipogenic enzymes are critical for the development and maintenance of the malignant
phenotype. Previous efforts to control oncogenic lipogenesis have been focused on
pharmacological inhibitors of FAS and ACC. Although they show anti-tumor effects in
culture and in mouse models, these inhibitors are non-selective blockers of lipid synthesis
in both normal and cancer cells. To target lipid anabolism in tumor cells specifically, it is
important to identify the mechanism governing hyperactive lipogenesis in malignant cells.
In the current study, we demonstrate that lysophosphatidic acid (LPA), a growth factor-
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like mediator present at high levels in ascites of ovarian cancer patients, regulates the
sterol regulatory element binding protein (SREBP)-FAS and AMP-activated protein
kinase (AMPK)-ACC pathways in ovarian cancer cells but not in normal or immortalized
ovarian epithelial cells. Activation of these lipogenic pathways is linked to increased de
novo lipid synthesis. The pro-lipogenic action of LPA is mediated through LPA2, a LPA
receptor subtype overexpressed in ovarian cancer and other malignancies. Downstream of
LPA2, the Gα12/13 and Gαq signaling cascades mediate LPA-dependent SREBP activation
and AMPK inhibition, respectively. Moreover, inhibition of de novo lipid synthesis
dramatically attenuated LPA-induced cell proliferation. These results demonstrate that
LPA signaling is causally linked to the hyperactive lipogenesis in ovarian cancer cells,
which can be exploited for development of new anti-cancer therapies.
2.1 INTRODUCTION
One of the most common molecular changes in tumor cells is the heightened rate
of de novo lipid synthesis compared to their normal counterparts. The aberrant
lipogenesis in cancer cells is mediated by increased expression and activity of key
lipogenic enzymes primarily fatty acid synthase (FAS) and acetyl-CoA carboxylase
(ACC). Interestingly, the alterations in these key lipogenic enzymes are critical for the
development and maintenance of the malignant phenotype (238). It occurs at early stages
of tumorigenesis and becomes more pronounced in advanced cancers (238,239).
Overexpression of FAS correlates with poor prognosis in several types of human
malignancies including ovarian cancer (240,241). Furthermore, tumor cells depend
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heavily on or are “addicted to” de novo lipid synthesis to meet their energetic and
biosynthetic needs, irrespective of the nutritional supplies in the circulation (238).
Consistent with this, pharmaceutical inhibitors of FAS suppress tumor cell proliferation
and survival, and enhance cytotoxic killing by therapeutic agents (158,242-246).
However, one barrier to cancer patient application of these inhibitors is their nonselective suppression of fatty acid synthesis in both normal and malignant tissues, which
could contribute to weight loss, anorexia, fatigue and other cancer-associated
complications. To target lipid anabolism in tumors specifically, it is important to identify
the mechanism for the hyperactive lipogenesis in cancer cells, which is, however, poorly
understood.
Lysophosphatidic acid (LPA), the simplest phospholipid, has been long known as
a mediator of oncogenesis (36). LPA is present at high levels in ascites of ovarian cancer
patients and other malignant effusions (36,247,248). LPA is a ligand of at least six G
protein-coupled receptors (GPCRs) (70). The LPA1/Edg2, LPA2/Edg4 and LPA3/Edg7
receptors are members of the endothelial differentiation gene (Edg) family, sharing 46 50% amino acid sequence identity (70). GPR23/P2Y9/LPA4 of the purinergic receptor
family and the related GPR92/LPA5 and P2Y5/LPA6 have been identified as additional
LPA receptors, which are structurally distant from the LPA1-3 receptors (70,249). The
Edg LPA receptors, in particular LPA2, are overexpressed in many types of human
malignancies including ovarian cancer (36,107). Strong evidence implicates LPA2 in the
pathogenesis of ovarian, breast and intestine tumors (83,107,113), although the exact
oncogenic processes involved remain elusive.
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In the present study, we observed that LPA stimulated proteolytic activation of two
isoforms of the sterol regulatory element binding proteins (SREBPs), transcription factors
involved in regulation of FAS and other lipogenic enzymes for biosynthesis of fatty acid
and cholesterol. In addition, LPA induces dephosphorylation of AMPKα at Thr-172 and
concomitant dephosphorylation of ACC at Ser-79. The dephosphorylation of ACC at Ser79 is associated with activation of the enzyme (250). These LPA-induced changes in the
lipogenic enzymes occurred hours after exposure to LPA and the effects were sustained
for many hours. Consistent with LPA activating these lipogenic pathways, LPA increased
de novo lipid synthesis. We identified LPA2, the receptor subtype overexpressed in
ovarian cancer and other human malignancies, as the key receptor responsible for
delivery of the lipogenic effect of LPA. The intracellular Gα12/13-Rho signaling cascade is
critical for LPA activation of the SREBP while Gαq-PLC is involved in LPA-mediated
dephosphorylation and inhibition of AMPK. These findings reveal a novel mode of the
cancer cell-specific regulation of lipogenesis by an intercellular factor present in the
circulation and tumor microenvironments.
2.2 EXPERIMENTAL PROCEDURES
Reagents – LPA (1-oleoly, 18:1) was obtained from Avanti Polar Lipids, Inc. (Alabaster,
AL). Prior to use, LPA was dissolved in PBS containing 0.5% fatty acid-free bovine
serum albumin (BSA) purchased from Roche (Indianapolis, IN). Acetic acid (1-14C) was
obtained from Moravek Biochemicals (Brea, CA). Plasmid DNA was purified using the
endo-free purification kit from Qiagen (Valencia, CA). The transfection reagent
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Dharmafect 1 was obtained from Dharmacon, Inc. (Lafayette, CO) and TransIT-TKO
was obtained from Mirus Bio (Madison, WI). Luciferase assay reagents were obtained
from Promega (Madison, WI). Anti-SREBP-1 and anti-SREBP-2 antibodies were
obtained from BD Biosciences (San Jose, CA). Anti-phospho-AMPKα (Thr-172), antiAMPKα, anti-phospho-ACC (Ser-79), anti-ACC, and anti-FAS antibodies were obtained
from Cell Signaling (Danvers, MA). Anti-Tubulin antibody was obtained from
EMD4Biosciences (Gibbstown, NJ). BODIPY 493/503 and cell culture reagents were
purchased from Invitrogen Inc. (Carlsbad, CA). The TaqMan Universal PCR Master Mix
and qPCR probes for LPA1, LPA2, LPA3, 3-Hydroxy-3-methylglutaryl-CoA (HGM-CoA)
reductase and GAPDH were obtained from Applied Biosystems (Carlsbad, CA). Calpain
I inhibitor, water soluble cholesterol, the FAS inhibitor C75, the ACC inhibitor TOFA
and sodium palmitate were purchased from Sigma-Aldrich (St. Louis, MO).
Cell Culture – The sources of ovarian cancer cell lines used in the study were described
previously (251). These cells were cultured in RPMI medium supplemented with 10%
FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin. IOSE-29 was originally obtained
from Dr. N. Auersperg (University of British Columbia, Canada) and cultured as
described previously (252).
siRNA, plasmids and transfection – The siRNA oligos for LPA1, LPA2 LPA3, and FAS
were obtained from Applied Biosystems. These siRNAs were transfected into cells using
Dharmafect 1 following the manufacturer’s protocol. In brief, cells were plated in 6-well
plates to reach 50-60% confluence before transfection. Cells were then transfected with
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target specific siRNA or non-targeting control siRNA (150 picoM) with Dharmafect 1 (4
µL) for 12-16 hours. Approximately 48 hours post transfection, the cells were serum
starved overnight before LPA treatment. Lentiviruses carrying short hairpin RNA
(shRNA) for LPA1-3 receptors were kind gifts from Dr. S. Huang (Medical College of
Georgia) (253). The expression vector pcDNA3 expressing dominant negative form of
Gαi was provided by Dr. P. Hylemon (Virginia Commonwealth University) (254,255).
The Gαq and Gα12 cDNAs were provided by Dr. RD Ye (University of Illinois at
Chicago). The dominant-negative mutants of Gαq (G208A) and Gα12 (G228A) (256-258)
in pcDNA3 were made using the QuikChange XL site directed mutagenesis kit
(Stratagene, Santa Clara, CA). The plasmids and the vectors expressing N19Rho and
Botulinum toxin C3 were described previously (259,260). These plasmids were
transfected into ovarian cancer cell lines using Lipofectamine LTX plus (Invitrogen)
following the manufacturer’s instruction.
Luciferase assays – The SREBP responsive luciferase reporter vector (pGL2–3xSREBPTK-Luc) was generated by cloning 3 repeats of the SREBP consensus sequence
(AAAATCACC

CCACTGCAAACTCCTCCCCCTGC)

(261,262)

into

the NheI

and HindIII sites in front of the herpes simplex virus thymidine kinase (TK) gene
promoter (–35 to +50) in the pGL2-TK-Luc vector (128). Ovarian cancer cell lines were
transfected with the luciferase vector using TransIT-TKO according to the
manufacturer’s protocol. About 48 hours after transfection, the cells were starved
overnight and treated with LPA or vehicle (BSA) for 12 hours. Cell extracts were
prepared and assayed for luciferase activity using the luciferase assay kits from Promega.
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Western blotting – Cells were lysed as previously described (263). Total cellular
proteins were resolved by SDS-PAGE, transferred to immunoblot membrane
(polyvinylidene difluoride) (BIO-RAD, Hercules, CA), and immunoblotted with
antibodies following the protocols of manufacturers. Immunocomplexes were visualized
with an enhanced chemiluminescence detection kit from Amersham (Piscataway, NJ).
Quantitative PCR (qPCR) – Total cellular RNA was isolated from cultured cells using
Trizol (Invitrogen). Complementary DNA (cDNA) was synthesized using the HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). The relative levels of
LPA1, LPA2, LPA3, HMG-CoA reductase and GAPDH were determined by qPCR using
gene specific probes, the TaqMan Universal PCR Master Mix, and the Applied
Biosystems 7900HT Real-Time PCR System.
Measurement of de novo lipid synthesis – Cells were grown in 6-well plates and serum
starved prior to treatment with LPA or vehicle for 24 hours. The cells were labeled with
14

C acetic acid (5 μCi/ml) for the last 6 hours of incubation. The cells were then washed

twice with PBS and lysed with lysis buffer (25 mM HEPES, 150 mM NaCl, 0.1% SDS, 1%
Triton X-100, 0.2 mM EDTA, 0.5% sodium deoxycholate, 20 mM glycerophosphate, 1
mM sodium vanadate, 1 mM PMSF, 10 μg/ml leupeptin and 10 μg/ml aprotinin). Lipids
were extracted using a chloroform: methanol solution (2:1). Phase separation was
achieved by centrifugation at 3200 x g for 10 minutes. The organic phase was extracted
and dried with speed vacuum. Lipids were dissolved in Ultima Gold Cocktail (Perkin
Elmer, Waltham, MA) and counted using Beckman LS 6500 scintillation counter. Each
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measurement was performed in triplicate and normalized to cell numbers.
Lipid staining – Cells were grown and serum starved prior to treatment with LPA or
vehicle for 24 hours. Cells were then stained with BODIPY 493/503 at final
concentration of 0.5 μg/ml in PBS at 37°C for 30 minutes, followed by counter staining
with Hoechst (10 μg/ml) for 15 minutes. Cells were then fixed with 2%
paraformaldehyde and visualized with fluorescence microscopy.
Quantification of triacylglycerols (TAG) and phospholipids – TAG and phospholipids
were extracted and quantified with the EnzyChrom Triglyceride Assay kit and the
EnzyChrom Phospholipid Assay kit (BioAssay Systems, Hayward, CA), respectively,
according to the manufacturer.
HPLC analysis of ATP/AMP ratio – Cells were serum starved for 16-18 hours prior to
LPA treatment. Nucleotides were extracted using 5% perchloric acid. Samples were then
subjected to HPLC analysis using BioBasic AX column. The phases A and B were 5 mM
KH2PO4 and 750 mM KH2PO4, respectively. The pH of both solutions (which both
solutions?) was adjusted to 3.2 using phosphoric acid. Nucleotides were separated using a
gradient of 0-100% of phase B in 30 min, at the flow rate of 1 ml/min and detected at 254
nm. The retention time for the AMP and ATP were obtained by running specific
standards, based on which corresponding peaks of samples were identified. Data
acquisition and analysis were carried out using the Shimadzu LC solution.

Anchorage-independent growth - Anchorage independent growth of cells was
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determined by soft agar assays in 6-well plates. Briefly, bottom layer of 0.6% soft agar in
complete medium was prepared. Following which and a top layer of 0.3% soft agar
including 3000 cells were applied into each well. After incubating the plates for 14 days,
colonies were stained with crystal violet solution and colonies were counted under
microscope.
Statistics – All numerical data were presented as mean ± SD. The statistical significances
of differences were analyzed using Student's t test where p<0.05 was considered
statistically significant. In all figures, the statistical significances were indicated with * if
p < 0.05 or ** if p < 0.01.
2.3 RESULTS
2.3.1 LPA INDUCES PROTEOLYTIC CLEAVAGE AND ACTIVATION OF
SREBP IN A CHOLESTEROL-SENSITIVE MANNER
Hyperactive lipogenesis is a hallmark of tumor cells (154,238). To identify
pathophysiological mechanisms driving the lipogenic program in cancer cells, we
examined the potential role of LPA, an endogenous regulator of many cellular functions
in ovarian cancer and other human malignancies. We first assessed whether LPA was
capable of activating the SREBP transcription factors that play crucial roles in regulating
expression of lipogenic enzymes. Treatment of Caov-3, OVCA-432 and other ovarian
cancer cell lines including OVCAR-3 with LPA induced cleavage of the precursor forms
of SREBP-1 and SREBP-2 in a time-dependent manner (Figure. 2.1). The cleaved,
mature forms of SREBP-1 and SREBP-2 were detectable at 4 hours and peaked at 12
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hours post LPA treatment. In contrast to the ovarian cancer cell lines, LPA failed to
activate SREBP-1 or SREBP-2 in the immortalized ovarian surface epithelial cell line
IOSE-29 (Fig. 2.1) or normal ovarian epithelial cells (data not shown), suggesting a
cancer cell-specific mechanism for SREBP activation by LPA in ovarian cancer cells.

Figure 2.1 LPA activates SREBP in ovarian cancer cells. Ovarian cancer cell lines
and IOSE-29 cells were treated with LPA (10 μM) for indicated periods of time. The
calpain inhibitor I (25 μg/ml) was added to cells for the last 2 hours. Expression of
SREBP-1 and SREBP-2 was analyzed by immunoblotting with antibodies that
recognize both precursor (p) and active/mature (m) forms of SREBP-1 and SREBP-2.

Under physiological conditions, SREBP-1 and SREBP-2 are regulated by the
intracellular sterol content. In their precursor forms, SREBPs are attached to the
endoplasmic reticulum (ER). Specific signaling cues such as reduced cholesterol levels
trigger SREBP cleavage-activating protein (SCAP)-mediated transport of SREBP from
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the ER to the Golgi, where they are cleaved by proteases S1P and S2P to release the
mature/active form (264). At high sterol concentrations, the SREBP/SCAP complex is
retained in the ER due to increased binding to INSIG proteins (265). To determine
whether LPA activation of SREBP could bypass cholesterol regulation, we preloaded
Caov-3 and OVCA-432 cells with cholesterol (10 μg/ml) complexed with 0.1% fraction
V fatty acid-free BSA in PBS, and then assessed activation of SREBP-1 in response to
LPA. As shown in Fig. 2.2A, cholesterol treatment reduced both basal and LPA-induced
active SREBP-1 levels, indicating that activation of SREBP by LPA remains sensitive to
cholesterol availability.
To determine whether LPA-induced SREBP cleavage is sufficient to activate
SREBP transcriptional activity, Caov-3 and OVCA-432 cells were transfected with the
SREBP responsive reporter pGL2–3xSREBP-TK-Luc. As shown in Fig. 2.2B, treatment
of transfected cells with LPA significantly enhanced luciferase activity in these cells.
Similar to the SREBP cleavage, SREBP-dependent luciferase activity was also sensitive
to cholesterol treatment (Fig. 2.2B).
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Figure 2.2 LPA activation of SREBP remains sensitive to cholesterol availability.
In A, Caov-3 and OVCA-432 cells were preloaded with or without cholesterol (10
μg/ml). The cells were treated with LPA and analyzed for expression of precursor and
mature forms of SREBP as in Fig. 2.1. In B, Caov-3 and OVCA-432 cells were
transfected with pGL2–3xSREBP-TK-Luc and loaded with or without cholesterol
before stimulation with LPA (10 μM) for 12 hours. The luciferase activity in cell
extracts was determined as described in Experimental Procedures and the results
presented as relative luciferase units (RLU).
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2.3.2 LPA INDUCES EXPRESSION OF THE SREBP TARGET GENES FAS,
ACC AND HMG-COA REDUCTASE
To substantiate the biological significance of SREBP activation by LPA, we
monitored expression levels of FAS, ACC, and HMG-CoA reductase. These are wellknown targets of SREBP-1 and SREBP-2 involved in biosynthesis of fatty acid and
cholesterol. Treatment of Caov-3, OVCA-432 and OVCAR-3 cells with LPA increased
expression levels of FAS and ACC proteins as shown in Fig. 2.3A. The mRNA levels of
these key enzymes for fatty acid synthesis (data not shown) and the rate-limiting enzyme
for cholesterol synthesis HMG-CoA reductase were also significantly increased by
treatment of ovarian cancer cell lines with LPA (Fig. 2.3B), providing evidence that
activation of SREBP-1 and SREBP-2 by LPA is sufficient to increase expression of key
endogenous lipogenic enzymes in ovarian cancer cells.
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Figure 2.3 LPA induces expression of the SREBP target genes FAS, ACC and
HMG-CoA reductase. Caov-3, OVCA-432 and OVCAR-3 cells were treated with or
without LPA (10 μM) for 16 hours prior to immunoblotting analysis of FAS and ACC
(A). Total cellular RNA was isolated from parallel samples and subjected to RT-qPCR
analysis of expression of HMG-CoA reductase mRNA (B). The results were presented
as fold increase relative to the value in the vehicle-treated cells (defined as 1).

2.3.3 LPA INDUCES DEPHOSPHORYLATION OF AMPK AND ACC
In addition to transcriptional upregulation, the activity of ACC is inhibited by
AMPK mediated phosphorylation. AMPK, a highly conserved protein serine/threonine
kinase, acts as an energy sensor and regulator of cellular metabolism, shutting down
energy-consuming anabolic processes and activating energy-yielding catabolic processes
(266). AMPK is activated through phosphorylation of Thr-172 within the activation
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domain of the α-subunit (267). To determine the effect of LPA on AMPK and its
downstream target ACC, we analyzed the phosphorylation status of AMPKα at this
residue as a surrogate of activation of the enzyme. Treatment of Caov-3 and OVCA-432
cells with LPA induced a late onset and sustained dephosphorylation of AMPKα (Fig.
2.4A). The decrease in AMPKα phosphorylation was detectable at 8 hours and became
prominent at 12 hours. Consistent with a predominant role of AMPKα in phosphorylation
of ACC, AMPKα dephosphorylation in LPA-treated cells was accompanied by a
decrease in ACC phosphorylation at Ser-79 (Fig. 2.4A). Dephosphorylation of this site is
known to enhance ACC enzymatic activity. The effects of LPA on dephosphorylation of
AMPKα and ACC were not detected in IOSE-29 cells (data not shown). These results
establish that, in ovarian cancer cells, LPA signaling is coupled to activation of ACC via
inhibition of AMPK. Moreover, we used HPLC to measure AMP/ATP ratios in Caov-3
cells treated with LPA for 12 hours. As seen in Fig 2.4B, LPA treatment led to a
significant decrease in cellular AMP/ATP ratio. The decreased the AMP/ATP ratio could
trigger the dephosphorylation/inactivation of AMPK seen in LPA-treated cells.
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Figure 2.4 LPA induces dephosphorylation of AMPKα and ACC. A. Caov-3 and
OVCA-432 cells were treated with or without LPA (10 μM) for the indicated periods
of time. The cell lysates were analyzed with immunoblotting for phosphorylation
status of AMPKα and ACC using their phospho-specific antibodies recognizing
AMPKα phosphorylated at Thr-172 or ACC phosphorylated at Ser-79. B. Caov3 cells
were serum starved overnight prior to LPA (10 μM) treatment for 12 hours.
Nucleotides were extracted and analyzed with HPLC as described in Experimental
Procedures.

2.3.4 LPA PROMOTES DE NOVO LIPID SYNTHESIS
Few studies have examined the role of exogenous factors in regulation of
lipogenesis in cancer cells (157,158). We next examined whether LPA-induced activation
of lipogenic enzymes is functionally sufficient to stimulate de novo lipid synthesis. The
ovarian cancer cell lines Caov-3 and OVCA-432, and the immortalized IOSE-29 cells
were treated with LPA or BSA as vehicle control and pulse labeled with 14C acetic acid to
monitor new lipid synthesis. As demonstrated in Fig. 2.5 (left), LPA treatment led to a
significant increase in

14

C incorporation into the cellular lipid fractions, reflecting an
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increase in newly synthesized lipids in response to LPA. The lipogenic effect of LPA was
specifically detected in multiple ovarian cancer cell lines but not in the non-transformed
IOSE-29 cells, wherein LPA failed to induce SREBP activation or AMPK
dephosphorylation. Since these cells were treated with LPA in serum-free medium
lacking extracellular fatty acids, we wanted to determine if the increase in lipogenesis in
response to LPA was influenced by availability of extracellular lipids. As shown in Fig.
2.5 (right), exogenously supplemented palmitate slightly reduced LPA-driven lipogenesis.
However, the reduction was statistically insignificant, indicating that the lipogenic role of
LPA is largely independent of availability of extracellular fatty acids.

Figure 2.5 LPA stimulates de novo lipid synthesis independently of availability of
extracellular fatty acids. Caov-3, OVCA-432 and IOSE-29 cells were treated with
LPA (10 μM) or BSA (vehicle) for 24 hours. In the last 6 hours of incubation, the cells
were pulse labeled with 5 μCi/ml of 14C acetic acid before lipid extraction as
described in Experimental Procedures. The incorporation of 14C into lipid fractions
was determined by scintillation counting. The results were presented as CPM per 1 x
106 cells (left). Caov-3 and OVCA-432 cells were treated with LPA in serum-free
medium supplemented with palmitate (10 μM) and BSA (0.01 %). LPA-induced
lipogenesis was measured as described above (right).
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Consistent with the pro-lipogenic action of LPA, staining with a lipophilic dye
BODIPY 493/503 revealed that LPA induced moderate increases in the intracellular
contents of neutral lipids in Caov-3 and OVCA-432 cells but not in IOSE-29 cells (Fig.
2.6A). These results were further supported by the increases in both cellular TAG and
phospholipids following LPA treatment (Fig. 2.6B & 2.6C).

Figure 2.6 LPA increases neutral and phospholipid contents. A. Cells in 6-well
plates were stained with BODIPY 493/503 fluorescent dye (0.5 μg/ml) for 30 minutes,
followed by staining with Hoechst (10 μg/ml) for 15 minutes to monitor neutral lipid
accumulation. Shown were fluorescence microscopic photographs of IOSE-29, Caov3 and OVCA-432 cells treated with or without LPA (x 80 magnification). Total TAG
(B) and phospholipids (D) in control and LPA-treated Caov-3 and OVCA-432 cells
were determined as described in Experimental Procedures. The results were presented
as amounts of lipids per well, or normalized on cell numbers to represent amounts of
lipids per million cells.
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2.3.5 LPA2 IS THE MAJOR RECEPTOR SUBTYPE RESPONSIBLE FOR
REGULATION OF SREBP AND AMPK
Caov-3, OVCA-432 and other ovarian cancer cell lines express the Edg LPA
receptors LPA1, LPA2, and LPA3 (Fig. 2.7A). The other non-Edg LPA receptors are
either absent or expressed inconsistently in ovarian cancer cells (94,268). Thus, we
focused on the potential role of LPA1-3 in the regulation of lipogenesis. We used siRNA
to knockdown expression of LPA1, LPA2, and LPA3 in Caov-3 cells and examined
SREBP activation and AMPKα dephosphorylation in response to LPA treatment.
Interestingly, only knockdown of LPA2 significantly attenuated LPA-induced cleavage of
SREBP-1, dephosphorylation of AMPKα at Thr-172 (Fig. 2.7B), and expression of FAS
and ACC (Fig. 2.7C). There was minimal inhibitory effect on SREBP-1 activation,
AMPKα dephosphorylation and expression of FAS and ACC in conjunction with LPA1
or LPA3 knockdown. We encountered a technical difficulty in achieving efficient
knockdown of LPA receptors with transient siRNA in OVCA-432 cells. However, similar
results were obtained from OVCA-432 cells when LPA receptors were stably knocked
down by lentivirus-transduced shRNA (Fig. 2.7B & 2.7C). These results support a
primary role of the LPA2 receptor in LPA-dependent activation of SREBP-1 and
inhibition of AMPKα. However, overexpression of LPA2 in IOSE-29 cells was not
sufficient to activate LPA-dependent induction of FAS and ACC (data not shown),
suggesting that additional signaling player(s) present specifically in malignant cells is
involved.
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To verify this receptor subtype-specific regulation of lipogenesis, we examined
the effect of LPA2 knockdown on LPA-driven lipogenesis. The de novo lipid synthesis in
LPA receptor knockdown and control cells was assessed as described earlier. The
endogenous lipid synthesis induced by LPA was strongly attenuated by siRNA- or
shRNA-mediated downregulation of LPA2 (Fig 2.7D). In contrast, knockdown of LPA3
(Fig. 2.7D) or LPA1 (data not shown) did not inhibit LPA-induced lipid synthesis.
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Figure 2.7 LPA2 mediates the lipogenic effect of LPA. A. Expression of mRNAs of
LPA1-3 receptors in IOSE-29, Caov-3 and OVCA-432 cells was determined by qPCR
analysis as detailed in Experimental Procedures. The results were presented as fold
difference relative to the mRNA levels of LPA receptors in IOSE-29 cells (defined as
1). B. Caov-3 cells were transfected with siRNA for each LPA receptor (LPA1si,
LPA2si and LPA3si) or with non-targeting control siRNA (Csi). Expression of each
LPA receptor in OVCA-432 cells was downregulated by lentivirus-transduced
shRNA. The knockdown efficiencies for each LPA receptor in both cell lines range
from 60 to 80% as determined by RT-qPCR analysis (data not shown). The cells were
stimulated with LPA (10 μM) for 12 hours before immunoblotting analysis of SREBP1 and phospho-AMPKα. In C, the effects of LPA2 knockdown on FAS and ACC
induction in Caov-3 and OVCA-432 cells were examined by immunoblotting analysis.
In D, the effects on lipid synthesis of siRNA or shRNA knockdown of LPA1, LPA2 or
LPA3 receptor in Caov-3 and OVCA-432 cells were measured as described in Figure
2.5.

2.3.6 LPA2 SIGNALING BIFURCATES TO REGULATE SREBP-1 AND AMPKα
We next examined the signaling effectors downstream of LPA2 responsible for
cleavage of SREBP-1 and dephosphorylation of AMPKα. The LPA1-3 receptors couple to
Gαi and Gαq, while only LPA1 and LPA2 couple to Gα12/13 (269). We transfected dominant
negative forms of these G proteins into highly transfectable Caov-3 cells in an effort to
screen for G proteins critical for LPA-dependent SREBP-1 cleavage and AMPKα
dephosphorylation. As shown in Fig. 2.8A, expression of the dominant negative Gα12
attenuated LPA-induced SREBP-1 cleavage but not LPA-induced dephosphorylation of
AMPKα. In contrast, expression of dominant negative Gαq inhibited AMPKα
dephosphorylation but not SREBP-1 cleavage induced by LPA. Thus, different G protein
cascades are implicated in the regulation of SREBP and AMPK by LPA. Since a
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prominent effector of Gα12/13 is the Rho GTPase, we examined whether Rho is required
for LPA activation of SREBP. As expected, expression of dominant negative Rho
(N19Rho) or Botulinum toxin C3, a specific inhibitor of Rho GTPase, suppressed LPAinduced cleavage of SREBP-1 (Fig. 2.8B) as compared to vector-transfected cells. The
results demonstrate that LPA2 promotes SREBP activation in a Rho-dependent pathway.
To determine the downstream effector of Rho that activates SREBP, we used inhibitors
for various pathways to determine their effect on LPA-induced SREBP transcriptional
activity. As shown in Figure 2.8C, Y-27632 (Rho-associated protein kinase, Rock
inhibitor) abrogated LPA-driven SREBP activity.
To elucidate the regulatory network leading to AMPK dephosphorylation, we
used pharmacological inhibitors of signaling molecules downstream of Gαq. As shown in
Fig. 2.8D, the PLC inhibitor U73122, but not it’s inactive analog U73433, blocked
AMPKα dephosphorylation induced by LPA. The data supports a Gαq-PLC-dependent
mechanism to control phosphorylation and activity of AMPKα in LPA-treated cells.
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Figure 2.8 LPA regulates SREBP and AMPK through different G protein
cascades. Caov-3 cells were transfected to express dominant negative forms of Gαi,
Gαq and Gα12 or the control vector. The transfected cells were treated with LPA (10
μM) for 12 hours before immunoblotting analysis of SREBP-1 cleavage and AMPKα
dephosphorylation (A). In B dominant negative Rho (N19Rho) or C3 toxin expression
vector was transfected into Caov-3 and OVCA-432 cells. The effects of N19Rho and
C3 toxin on LPA-induced SREBP-1 cleavage were analyzed by immunoblotting. In C,
Caov3 cells were transfected with pGL2-3XSRE-TK-luc construct and treated with
(10 μM) LPA alone or in the presence of the indicated inhibitors for 12 hours and
subsequently assayed for luciferase activity. Concentrations of inhibitors used are as
follows: PD98059 (10 μM), rapamycin (0.1 nM), Y-27632 (10 μM). In D, Caov-3 and
OVCA-432 cells were treated with LPA in the presence of the PLC inhibitor U73122
or its inactive analog U73433 (10 μM). LPA-induced AMPKα dephosphorylation was
analyzed by immunoblotting.
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2.3.7 LPA-DRIVEN CELL PROLIFERATION REQUIRES LPA2 AND DE NOVO
LIPID SYNTHESIS
LPA is a mitogen that stimulates proliferation of ovarian cancer cells (52,270272). To understand the biological significance of LPA-induced lipogenesis, we
examined whether the pro-lipogenic activity of LPA contributes to LPA-driven
proliferation of ovarian cancer cells. C75 and TOFA are well characterized, specific
inhibitors of FAS and ACC, respectively (273,274). The presence of C75 dramatically
decreased cell numbers of Caov-3 and OVCA-432 in serum-free medium supplemented
with LPA as a growth factor (Fig. 2.9A), suggesting that the blockade of de novo
lipogenesis could attenuate LPA-induced cell proliferation. Similar effects were observed
in the presence of the ACC inhibitor TOFA (data not shown). At the concentrations we
used, C75 and TOFA did not induce significant increases in apoptosis or appreciable
decreases in cell viability (data not shown), suggesting that these inhibitors mainly
targeted cell proliferation rather than cell survival. We also tested if exogenously added
palmitate could reverse the effect of C75 on LPA-induced cell proliferation. At 10 μM,
palmitate partially prevented the effect of C75 (Fig. 2.9B). This ability of palmitate,
however, was not seen at 20 μM, suggesting a possible cytotoxic effect of high
concentrations of palmitate. To obtain molecular evidence for the involvement of FAS in
LPA-induced cell proliferation, we used siRNA to knockdown FAS expression in Caov-3
and OVCA-432 cells. Downregulation of FAS expression indeed prevented proliferation
of these cells induced by LPA (Fig. 2.9C).
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Figure 2.9 Inactivation of FAS attenuates LPA-induced cell proliferation. Caov-3
and OVCA-432 cells in 6-well plates were incubated for 48 hours in serum-free
medium supplemented with 10 μM LPA in the presence of indicated concentrations of
the FAS inhibitor C75 (A). In B, Caov-3 and OVCA-432 cells were incubated with
LPA (10 μM) and C75 in the presence of the indicated concentrations of palmitate.
BSA was kept at a final concentration of 0.01% for all treatments. In C, expression of
FAS was downregulated by siRNA knockdown in Caov-3 and OVCA-432 cells to
examine LPA-induced cell proliferation after 48 hours of incubation with 10 μM LPA.
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Finally, since LPA2 is the key receptor subtype required for LPA activation of
lipogenesis, we knocked down its expression to determine whether LPA2 is an integral
component of LPA-induced cell proliferation. As shown in Fig. 2.10A, following
downregulation of LPA2, both cell lines exhibited a significant decrease in growth rate
when the cells were incubated in serum-free medium containing LPA. Since LPA is a
component of serum, we wondered if LPA signaling contributed to proliferation under a
physiological setting. We observed that stable knockdown of LPA2 resulted in reduced
growth of OVCA-432 cells grown in serum containing media (Fig. 2.10B). LPA2 was
also critical for anchorage-independent growth of ovarian cancer cells, as stable
knockdown of LPA2 in OVCA-432 cells inhibited the numbers and sizes of colonies
grown in soft agar (Fig. 2.10C). Thus LPA2 and its associated lipogenesis-promoting
activity are critical for anchorage-dependent and independent growth of ovarian cancer
cells.
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Figure 2.10 LPA2 is required for cell proliferation and anchorage-independent
growth. A. LPA2 was downregulated by siRNA or shRNA in Caov-3 and OVCA-432
cells. The growth of these cells in serum-free medium supplemented with 10 μM LPA
was examined after 48 hours of incubation. Cell numbers were quantitated with
Coulter counter and presented as mean ± SD of triplicate assays, representative of
three independent experiments. B. OVCA-432 cells were plated in 12 wells dishes in
equal numbers and cell numbers were counted every 24 hours using coulter counter.
C. OVCA-432 cells were plated in 6-well plates (3000 cells/well) coated with 0.6%
soft agar and allowed to grow for two weeks. After which photographs were taken
under microscope and colony numbers were quantified. Bar represents 2000 µM.
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2.4 DISCUSSION
The majority of adult tissues depend on dietary fat to meet their nutritional needs.
In contrast, cancer cells depend on de novo lipid synthesis for generation of fatty acids,
irrespective of the available extracellular supplies. Malignant cells typically show a high
rate of de novo fatty acid synthesis (136,275). Intracellular fatty acids in rapidly dividing
cancer cells not only supply energy through beta oxidation but more importantly, serve as
precursors for biosynthesis of membrane phospholipids, signaling lipids and secondary
messengers (155). The lipogenic phenotype of cancer cells has been primarily attributed
to increased expression or aberrant activity of the major lipogenic enzymes FAS and
ACC. In particular, FAS, originally recognized as a tumor specific antigen present in
serum of cancer patients (154), is overexpressed in a variety of human malignancies.
However, the cellular mechanisms by which lipogenic enzymes are upregulated in cancer
cells remain poorly understood, except for a few studies suggesting that steroid hormones
and Her family ligands could increase FAS expression via the PI3K or MAPK pathways
(160,161,276,277).
In the present study, we describe a novel LPA-mediated mechanism activating de
novo lipogenesis in ovarian cancer cells. We demonstrated that treatment of ovarian
cancer cell lines with LPA activates the SREBP-FAS and AMPK-ACC lipogenic
cascades, culminating in increased de novo lipid synthesis. The lipogenic effect of LPA
was specifically observed in cancer cells as LPA failed to induce de novo lipogenesis in
non-transformed IOSE-29 cells. LPA has been long known as a mediator of ovarian
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cancer. It is present at high concentrations in tumor microenvironments such as ascites of
ovarian cancer patients and other malignant effusions (247,248). The present study
highlights the possibility that LPA is an etiological factor in tumor microenvironments to
promote lipogenesis in ovarian cancer cells, although the effect of LPA in other cancer
cells remains to be determined.
A significant finding of the present work is the selective role of the LPA2 receptor
in LPA activation of the lipogenic pathways and LPA-driven lipogenesis. We and others
have previously shown that LPA2 and LPA3 are overexpressed in significant fractions of
ovarian cancers and in most ovarian cancer cell lines (107,272). LPA1, which is
expressed by both normal and malignant ovarian epithelial cells, is dispensable for the
pro-lipogenic activity of LPA in ovarian cancer cells. It is somewhat surprising that in
both Caov-3 and OVCA-432 cells, knockdown of LPA3 slightly potentiated the lipogenic
effect of LPA (Fig. 2.7D). The results imply that the crosstalk among co-expressed LPA
receptors is important in the control of biological outcomes of LPA. The specific role of
LPA2 in the promotion of lipogenesis in tumor cells is consistent with the increased
expression of this receptor in various malignancies (107,108,110,111). Although LPA1
and LPA3 have also been reported to be up or down-regulated in some cancers,
overexpression of LPA2 is most commonly seen in almost all cancer types examined
(107,108,110,111). There is also strong evidence from xenograft mouse models and
transgenic mice that LPA2 is more oncogenic compared to LPA1 and LPA3 (83,84). The
compelling evidence for the implication of LPA2 as an oncogene stems from recent
studies by Yun’s group who showed the LPA2-deficient mice were more resistant to
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intestinal tumorigenesis induced by colitis or by ApcMin mutation (112,113). However,
the molecular mechanisms for the oncogenic activity of LPA2 are not well understood.
Most previous studies have been focused on the ability of LPA2 to stimulate expression
of oncogenic protein factors including IL-6, VEGF, HIF1α, c-Myc, cyclin D1, kruppellike factor 5, and Cox-2 (112,113,128,129,131,278). LPA2 seems to be more potent than
other LPA receptors in driving the transcriptional effects of LPA on these LPA target
genes. The current study links LPA2 to the lipogenic phenotype of ovarian tumor cells.
The role of LPA2 in lipid metabolism provides a new avenue to explore the oncogenic
role of LPA.
Different G proteins downstream of LPA2 are involved in regulation of the
SREBP-FAS and AMPK-ACC pathways in LPA-treated cells. Our results showed that
SREBP cleavage/activation lies downstream of the G12/13-Rho pathway, while AMPK
dephosphorylation/inhibition is mediated by the Gq-PLC cascade. LPA stimulated
cleavage of the precursor SREBP into mature and active forms in a time-dependent
manner, which was accompanied by increases in SREBP-dependent transcriptional
activity and upregulation of endogenous SREBP target genes. In addition, the effect of
LPA on SREBP cleavage and activation remains sensitive to cholesterol-mediated
regulation, indicating that the sterol sensing machinery involved in SREBP cleavage is
not disrupted by LPA. The proteolytic cleavage of SREBP is controlled by the combined
action of SCAP and INSIG proteins (279). An increase in SCAP or decrease in INSIG
proteins could lead to activation of SREBP. Since androgens and insulin have been
shown to regulate expression or stability of SCAP or INSIG proteins (179,280), it will be
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of interest to determine whether LPA modulates these proteins or their ratios to activate
SREBP. This possibility is consistent with the observation that SREBP cleavage occurs
hours after exposure of ovarian cancer cells to LPA.
It is yet to be determined how the Gq-PLC pathway is linked to dephosphorylation
and inhibition of AMPKα. Obviously, our observation does not agree with Kim et al. who
recently reported that LPA stimulated transient phosphorylation of AMPKα at Thr-172
within the first 10 minutes of LPA treatment in the SKOV-3 ovarian cancer cell line
(281). In our experiments involving multiple ovarian cancer cell lines, there was little
change in AMPKα phosphorylation status at the early time points. Instead, we observed a
time-dependent decrease in phospho-AMPKα levels, which maximized after 12 hours of
incubation with LPA. The serine-threonine kinase LKB1, encoded by the Peutz-Jeghers
syndrome tumor suppressor gene, is believed to be the primary AMPK kinase as
suggested by LKB1 knockout studies (282-284). LKB1 possesses a nuclear localization
domain and is located predominantly in the nucleus. Upon phosphorylation, LKB1
translocates to the cytoplasm where it forms an active complex with Ste20-related
adaptor (STRAD) and mouse protein 25 (MO25) (285). LPA may downregulate LKB1
activity via modulation of its phosphorylation, nuclear-cytoplasmic translocation or
association with STRAD-MO25 in the cytosol. In addition, AMPK phosphorylation
could be downregulated by inhibition of other candidate AMPK kinases such as
calmodulin-dependent protein kinase kinase-beta (CAMKKβ) (285) or by activation of
unknown AMPK phosphatase(s). A decrease in the AMP/ATP ratio in LPA-treated cells
as shown in Fig. 2.4B could also change the conformation of AMPK to prevent the active
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site (Thr-172) on the α-subunit from being exposed and phosphorylated by AMPK
kinases.

CHAPTER 3

LYSOPHOSPHATIDIC ACID ACTIVATES HEXOKINASE-2 EXPRESSION
AND GLYCOLYSIS IN CANCER CELLS
3.0 ABSTRACT
Most malignancies exhibit the “Warburg effect”- a phenomenon characterized by
an enhanced glycolytic rate, thereby replacing oxidative phosphorylation as the major
ATP generating process. Hyperactive glycolysis leads to increased carbon flux and
abundant metabolic precursors which are required to maintain the high rate of
biosynthesis of structural and signaling lipids and other cellular components required
during rapid tumor cell division. Glycolytic enzymes are classically activated by hypoxia
and its principal mediator hypoxia-inducible factor (Hif-1α). Here we describe regulation
of this process under normoxic conditions by lysophosphatidic acid (LPA). We showed
that LPA dose-dependently enhanced the glycolytic rate and subsequent lactate efflux in
ovarian, breast and lung cancer cells, but failed to elicit these effects in non-transformed
epithelial cells, suggesting a cancer cell-specific regulation of glucose metabolism by
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LPA. We found that the LPA receptor 2, a receptor subtype overexpressed in various
malignancies including ovarian and breast cancer, was the major LPA receptor
underlying the pro-glycolytic action of LPA. RT-qPCR array analysis revealed a number
of glycolytic genes up- or down- regulated in response to LPA. Among them, hexokinase
2 (HK-2) was the most dramatically induced by LPA and promoted the glycolytic
activation in LPA-treated ovarian cancer cells. Mutation and deletion analysis of the
human HK-2 gene promoter identified two sterol regulator elements (SREs) responsible
for LPA activation of the promoter. Moreover, DNA pull down assays demonstrated that
these SREs bound to sterol regulatory element binding protein-1 (SREBP-1) in LPAtreated cells where SREBPs were proteolytically activated by LPA, as we described
recently. Binding of SREBP-1 to the native HK-2 promoter upon LPA stimulation was
further confirmed by chromatin immunoprecipitation assays. In addition to activation of
the SREBP-1-HK-2 cascade, LPA treatment also stabilized Hif-1α protein in cancer cell
lines. However, LPA enhanced HK-2 expression and glycolysis largely independently of
Hif-1α. These results established a novel role of LPA in regulation of glucose metabolism
via LPA2-SREBP-1-dependent activation of HK-2 expression in neoplastic cells.
Combined with our recent discovery of LPA’s lipogenic effect (CHAPTER 2), our results
indicate that aberrant LPA signaling is causally linked to the lipogenic and glycolytic
phenotypes of cancer cells.
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3.1 INTRODUCTION
Hyperactive glycolysis is one of the fundamental changes observed in
transformed cells. First identified by Otto Warburg in 1920s, this observation suggests
that cancer cells preferentially utilize glycolysis to generate ATP, even in the presence of
oxygen, resulting in enhanced lactate efflux (135). Recent studies, however, indicate that
ATP production is probably secondary to the effect that glycolysis has on biomass
generation (193) . Transformed cells have a high rate of proliferation and to sustain this
effect, cells need to upregulate their synthetic machinery. Glycolysis serves as a primary
route for carbon influx, which is required to generate complex macromolecules and
organelles in the cell. The molecular mechanisms regulating aerobic glycolysis vary
among cancers and a fundamental cause remains to be elucidated. However, upregulation
and mutational activation of certain metabolic enzymes along with deregulated growth
factor signaling have been found to affect cancer cell metabolism (286,287). Several
glycolytic enzymes have been found to be upregulated in various cancers, and one of the
most frequently upregulated enzymse is Hexokinase 2 (HK-2) (219,288). HK-2 catalyzes
one of the rate limiting steps of glycolysis, converting glucose to glucose-6-phosphate at
the expense of one ATP molecule. In mammals, there are four isozymes of hexokinase
which vary in their affinity for glucose, tissue distribution and their physiological
functions (289). HK-2 is localized to the mitochondrial outer membrane and has been
reported to be associated with the voltage-dependent ion channel (VDAC) (216), thereby
gaining access to ATP from the inner mitochondrial ATP synthase (290).
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LPA is an oncogenic lysophospholipid mediator, elevated in the circulation and
malignant effusions of cancer patients (30). LPA is known to regulate diverse biological
processes including proliferation, migration, invasion, and cell survival (51). These
effects of LPA are mediated via binding to its cognate G-protein coupled receptors
(GPCRs). LPA1, LPA2 and LPA3 are LPA receptors that belong to the endothelial gene
(Edg) subfamily of GPCRs. The purinergic family receptor LPA4 and related LPA5, LPA6
and LPA7 receptors constitute the non-Edg subgroup of LPA receptors, which are
structurally distant from the Edg LPA receptors (70). These LPA receptors are expressed
differentially in adult tissues (70). Accumulating evidence suggests that LPA receptors
are not functionally identical (70), hence the cellular effects of LPA depend on the
combination of various LPA receptors present in a cell. Among LPA receptors, LPA2 has
been the most consistently shown to be upregulated in diverse human malignancies
including cancers of ovary, breast (108), stomach (109), colorectal (110) and thyroid
(111). LPA2 mediated signaling has been shown to induce pro-oncogenic factors such as
IL-6, IL-8, VEGF and to increase ovarian cancer cell proliferation and tumor burden in
xenograft studies (83). Overexpression of LPA2 has also been linked to proliferation of
colon and breast cancer cells and mesothelioma cells (84,99,291). Although LPA2 is
known to activate various mitogenic and pro-survival pathways, the exact mechanism
responsible for its oncogenic role is yet to be determined.
In this study, we provide evidence that LPA signaling contributes to the Warburg
effect in various cancer cells. We show that LPA activates glycolysis and lactate efflux in
cancer cells but not in non-transformed, immortalized epithelial cells. We identified HK-
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2 as a major glycolytic enzyme upregulated by LPA to promote glycolysis. The detailed
analysis of the HK-2 gene promoter led to identification of SREBP-1 as the key
transcription factor to mediate LPA induction of HK-2. The effects of LPA on HK-2 and
glycolysis were independent of Hif-1α, a major regulator of glycolytic enzymes under
hypoxic conditions (233). Furthermore, we identified LPA2 to be the primary LPA
receptor subtype mediating the effects of LPA on HK-2 expression and glycolysis. These
findings provide a novel route for upregulating aerobic glycolysis in cancer cells by a
previously unrecognized pro-glycolytic factor LPA.
3.2 EXPERIMENTAL PROCEDURES
Reagents – LPA (1-oleoly, 18:1) was obtained from Avanti Polar Lipids, Inc. (Alabaster,
AL). Prior to use, LPA was dissolved in PBS containing 0.5% fatty acid-free bovine
serum albumin (BSA) purchased from Roche (Indianapolis, IN). Plasmid DNA was
purified using the endo-free purification kit from Qiagen (Valencia, CA). The
transfection reagent Dharmafect 1 was obtained from Dharmacon, Inc. (Lafayette, CO)
and TransIT-TKO was obtained from Mirus Bio (Madison, WI). Luciferase assay
reagents were obtained from Promega (Madison, WI). Anti-SREBP-1, SREBP-2 and Hif1α antibodies were obtained from BD Biosciences (San Jose, CA). Anti-HK-2 antibody
was obtained from Cell Signaling (Danvers, MA). Anti-Tubulin antibody was obtained
from EMD4Biosciences (Gibbstown, NJ). The TaqMan Universal PCR Master Mix and
qPCR probes for HK-2, PGK1 and GAPDH were obtained from Applied Biosystems
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(Carlsbad, CA). Calpain I inhibitor was purchased from Sigma-Aldrich (St. Louis, MO).
D-[5-3H(N)]-glucose was purchased from Perkin Elmer (Boston, MA).
Cell Culture – The sources of ovarian and breast cancer cell lines used in the study were
described previously (251). Lung cancer cells H838, H2347 and NHBE cells were kindly
provided by Dr. Charles Chalfant, VCU. These cancer cell lines were cultured in RPMI
medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.
The non-transformed NHBE cells were cultured in keratinocyte serum free medium
(Invitrogen, Carlsbad, CA).
siRNA, plasmids and transfection – The siRNA oligos for LPA1, LPA2 LPA3, Hif-1α,
SREBP-1 and HK-2 were obtained from Applied Biosystems. These siRNAs were
transfected into cells using Dharmafect 1 following the manufacturer’s protocol. In brief,
cells were plated in 6-well plates to reach 50-60% confluence before transfection. Cells
were then transfected with target specific siRNA or non-targeting control siRNA (150
picoM) with Dharmafect 1 (4 μL) for 12-16 hours. Approximately 48 hours post
transfection; the cells were serum starved overnight before LPA treatment.
Western blotting – Cells were lysed as previously described (263). Total cellular
proteins were resolved by SDS-PAGE, transferred to immunoblot membrane
(polyvinylidene difluoride) (BIO-RAD, Hercules, CA), and immunoblotted with
antibodies following the protocols of manufacturers. Immunocomplexes were visualized
with an enhanced chemiluminescence detection kit from Amersham (Piscataway, NJ).
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Quantitative PCR (qPCR) – Total cellular RNA was isolated from cultured cells using
Trizol (Invitrogen). Complementary DNA (cDNA) was synthesized using the HighCapacity cDNA Reverse Transcription Kit (Applied Biosystems). The relative levels of
LPA1, LPA2, LPA3, HK-2 and GAPDH were determined by reverse transcription (RT)
followed by qPCR using gene specific probes, the TaqMan Universal PCR Master Mix,
and the Applied Biosystems 7900HT Real-Time PCR System.
Luciferase vectors and luciferase assays- The human HK-2 promoter sequence (-1476
to +73) was PCR amplified and cloned into the pGL2-Basic-Luc vector to construct the
luciferase reporter vector pGL2-1476-HK-2-Luc. The PCR product was inserted into
pGL2-Basic-Luc at XhoI and HindIII sites. The truncated forms (-478 to +73 and -273 to
+73) were made by PCR amplification of the corresponding fragments from pGL2-1476HK-2-Luc and re-inserted into the pGL2-Basic-Luc at the XhoI and HindIII sites. The
promoter sequences in these plasmids were verified by automatic sequencing. Two
potential

SREBP

consensus

sites

(CCAGTCGCCCACACC

and

CACGCTCCCCCCACCA) within pGL2-1476-HK-2-Luc were converted into inactive
(CCAGGTGTCTTACACC and CACGCGTCTCTTACCA) sequences by site-directed
mutagenesis using Lightning Site-Directed Mutagenesis Kit (Stratagene) following
the manufacturer’s protocol. Primers used for these mutant constructs were listed in
Table 3.1. Caov3 cells were transfected with the luciferase vector using TransIT-TKO
according to the manufacturer’s protocol. About 48 hours after transfection, the cells
were starved overnight and treated with LPA or vehicle (BSA) for 12 hours. Cell extracts
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were prepared and assayed for luciferase activity using the luciferase assay kits from
Promega.
PCR array - Human glucose metabolism, RT2 profiler PCR Array were obtained from
SABiosciences (Qiagen). Caov-3 cells were treated with LPA or vehicle control for 12
hours before RNA isolation using RNeasy mini kit (Qiagen). The Tissue Scan TM Cancer
and Normal cDNA arrays for human lung cancer (HLRT102) were obtained from
Origene and qPCR was performed using the Taqman mix and probes for LPA2 and HK-2.
The results were normalized to the levels of β-actin.
Measurement of glycolytic rate – Glycolysis was measured as describes (292) with a
few modifications. Briefly, cells were plated in 12 well dishes, serum starved and treated
with vehicle (BSA) or LPA for 16 hours. At the 12th hour of LPA treatment, 5-3H (N)
glucose was added to the medium at a concentration of 1μCi/ml and incubated for the
remaining 4 hours. Post treatment, hydrochloric acid was added to the medium at a final
concentration of 0.2 N to terminate all biological reactions. The acidified medium was
collected in a 15 ml tube. A 0.5 ml micro centrifuge tube containing 0.25 ml distilled
water was uncapped and inserted into the 15 ml tube. Precautions were taken to make
sure the two liquids remained separate. The 15 ml tubes were sealed to allow diffusion
between two liquid phases for more than 24 hours. The glycolytic rate was calculated
based on the ratio of the radioactivities present in water and in medium determined by
liquid scintillation counting (293) .
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Lactate measurement – Cells were treated with LPA or vehicle (BSA) for 16 hours
before the culture supernatants were collected. The lactate contents were then determined
using the lactate assay kit (Eton Bioscience, San Diego, CA) following the
manufacturer’s protocol.
Hexokinase activity assay –Cells were lysed with a lysis buffer containing 15 mM Tris
pH 7.8, 0.25 mM sucrose, 0.5 mM dithiothreitol (DTT), 1 mM aminohexanoic acid, 1
mM phenylmethylsulfonyl fluoride (PMSF) and 2 μg/ml leupeptin. The lysates were then
sonicated (5 time for 30 seconds each) in a water bath, followed by centrifugation at 2000
g at 4°C for 5 min. The cell extracts (50 µl) were added to 950 µl of reaction buffer (100
mM Tris-HCl, pH 7.8, 5 mM ATP, 10 mM MgCl2, 10 mM glucose, 0.4 mM NADP, and
0.15 U/ml of G6PD (Sigma-Aldrich) and incubated at 37°C. HK enzymatic activity was
determined by following the G6P-dependent conversion of NADP to NADPH
spectrophotometrically at 340 nm. One unit of activity was defined as micromoles of
NADPH per milligram of protein per minute at 37°C.
DNA pull-down assay –Nuclear proteins was isolated from vehicle (BSA) or LPA
treated cells as described previously (133). Equal amounts of nuclear proteins were
incubated with 4 µg of biotinylated double-stranded oligonucleotides which contains wild
type HK-2 promoter sequence or its mutated counterpart (Table 3.1) for 16 hours at 4 °C.
The M-280 Streptavidin Dynabeads (Invitrogen) (30 µl) were then added to each sample
and incubated for another hour at 4 °C. The Dynabeads were washed three times with
PBS before western analysis of SREBP-1 and SREBP-2.
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Chromatin immunoprecipitation (ChIP) assay - Vehicle or LPA treated cells were
cross-linked with 1% formaldehyde for 10 minutes at room temperature. The cells were
then lysed for 10 minutes in ice-cold lysis buffer (5 mM HEPES, pH 8.0, 80 mM KCl, 1%
NP40 and protease inhibitors). The nuclear pellet was recovered by centrifugation (5
minutes at 5000×g) and resuspended in a nuclear lysis buffer (50 mM HEPES, pH 8.0, 10
mM EDTA, 1% SDS, protease inhibitors) and sonicated on ice to achieve an average
chromatin length of 200-1000 bp. The sonicated samples were pre-cleared by incubation
with Protein G Dynabeads (Invitrogen) and protein concentrations were determined by
BCA protein estimation kit (Pierce). Equal amounts of proteins were incubated for 16
hours at 4 °C with 2 μg of either normal rabbit IgG (Santa Cruz) or rabbit anti-SREBP-1
antibody. Protein G Dynabeads was subsequently added and incubated for 2 hours. The
DNA-protein-beads were washed sequentially once with a low salt buffer (20 mM Tris,
pH 8.0, 150 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton 100), once with a high salt
buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton 100),
once with LiCl buffer (10 mM Tris-HCl, pH 8.0, 0,25 M LiCl, 1 mM EDTA, 1%
deoxycholate, 1% NP-40), and finally twice with TE buffer (10 mM Tris-HCl, pH 8, 1
mM EDTA). The specifically bound complexes were eluted from the Protein G
Dynabeads by incubation twice with TE elution buffer (10 mM Tris-HCl, pH 8, 1
mM EDTA, 1% SDS) at 65 °C for 15 minutes. The immunoprecipitated complexes and
the inputs were the reverse cross linked by incubating samples overnight at 65 °C. The
samples were then treated with RNase A and proteinase K and subsequently DNA was
purified using the QIAquick Spin Columns and analyzed by PCR amplification of the
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HK-2 promoter sequence using primers listed in Table 3.1.
Statistics - All numerical data were presented as mean ± SD of triplicate assays,
representative of three independent experiments. The statistical significances were
analyzed using Student's t test, unless otherwise stated, p<0.05 was considered
statistically significant. In all figures, the statistical significances were indicated with * if
p<0.05 or ** if p<0.01.
Table 3.1 Oligonucleotides used in study
Luciferase primers
-1476 fwd
5’-GCACTCGAGGGATTATGATTTTTGTTTATTTTTCCT-3’
+73 rvs
5’-GCAAAGCTTCGGATTTTCTTAGCTGGGTG-3’
-478 fwd
5’-GCACTCGAGCCGGCCGTGCTACAATAG-3’
-273 fwd
5’ -GCACTCGAGCTCATGCGCCTTTCCGTC-3’
SRE1 Mut fwd
5’-CAGAGGCCCGTTTTTCCAGGTGTCTTACACCCCGGGTCC
GCGAT-3’
SRE1 Mut rvs
5’-ATCGCGGACCCGGGGTGTAAGACACCTGGA AAA ACG
GGC CTC TG-3’
SRE2 Mut fwd
5’-GGGTCCGCGATCACGCGTCTCTTACCCATAGCCGAGCCTG3’
SRE2 Mut rvs
5’CAGGCTCGGCTATGGGTAAGAGACGCGTGATCGCGGACCCG3’
DNA pull-down oligonucleotides
HK-2 WT fwd
5’CGTTTTTCCAGTCGCCCCACACCCCGGGTCCGCGATCACGCT
CCCCCCACCCATAG CCGA-3’
HK-2 WT rvs
5’TCGGCTATGGGTGGGGGGAGCGTGATCGCGGACCCGGGGTG
TGGGGCGACTGGAAAAACG -3’
HK-2 Mut fwd
5’CGTTTTTCCAGGTGTCTTACACCCCGGGTCCGCGATCACGCG
TCTCTTACCCATAGCCG -3’
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HK-2 Mut rvs

ChIP primers
-478 SRE fwd
-478 SRE rvs
-1476 SRE fwd
-1476 SRE rvs

5’TCGGCTATGGGTAAGAGACGCGTGATCGCGGACCCGGGGTG
TAAGACACCTGGAAAAACG -3’
5’- AGAGGCCCGTTTTTCCAGTCG -3’
5’- GCTAAAGGCTGGGACGGAAAGG -3’
5’- GGAAGTTTTGCTGAGAGGCT -3’
5’- AAGATGAAGGTCTGCCATGTTC -3’

3.3 RESULTS
3.3.1 LPA ACTIVATES GLYCOLYSIS IN OVARIAN CANCER CELLS
LPA is found in abundance in ascites of ovarian cancer patients (248,294). In this
study, we examined whether LPA signaling promotes aerobic glycolysis, a hallmark of
ovarian and other cancer cells. During glycolysis, one molecule of water is released as 2phosphoglycerate is converted to phosphoenolpyruvate. By labeling cells with 3H-glucose
we were able to quantitate the glycolytic rate by measuring generation of 3H water in
culture supernatants. We treated a panel of ovarian cancer cell lines and an immortalized
ovarian surface epithelial cell line IOSE-80 with (10 μM) LPA and labeled the cells with
5-3H-glucose. As shown in Figure 3.1A, LPA treatment led to a dramatic increase in
glycolytic rate in ovarian cancer cell lines, but failed to elicit this effect in the nontransformed IOSE-80 cells. The LPA mediated increase in glycolysis was concurrent
with a significant increase in lactate efflux from ovarian cancer cell lines. Consistent with
the lack of stimulation of glycolysis by LPA in IOSE-80 cells, no net increase in lactate
production was observed (Figure 3.1B). Moreover, the effect of LPA on glycolysis in
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ovarian cancer cell lines was dose dependent (Fig. 3.1C), with significant stimulation
observed at as low as 1 μM. The optimal activity was observed with 10 μM LPA.

Figure 3.1 LPA activates glycolysis in ovarian cancer cells. A. IOSE-80 and
ovarian cancer cell lines were treated with LPA (10 μM) or BSA (vehicle) for 16
hours. In the last 4 hours of incubation, cells were pulse labeled with 1μCi/ml of 3H
glucose before glycolytic rate was measured as described in Experimental Procedures.
The results were presented as relative fold increase over vehicle treated control cells
(defined as 1.0). B. Culture supernatants of the cell lines treated with LPA or BSA for
16 hours were collected and lactate concentrations were determined as described in
Experimental Procedures. C. Caov-3 cells were treated with indicated concentrations
of LPA and glycolytic rate was measured and presented as in A.
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3.3.2 LPA ACTIVATES TRANSCRIPTION OF GENES INVOLVED IN
GLUCOSE METABOLISM
LPA is known to transactivate a variety of pro-oncogenic protein factors such as
VEGF, COX-2, IL-6, IL-8, cyclin D1 and kruppel-like factor 5 (112,113,128,129,131).
We wanted to determine if LPA transcriptionally activated genes involved in the
glycolytic pathway, which could explain the enhanced glycolytic flux observed in ovarian
cancer cell lines. We treated Caov-3 cells with LPA or its vehicle control for 12 hours
and isolated RNA to determine the effect of LPA on glucose metabolism using an RTqPCR array for genes involved in glucose metabolism (SABioscience). LPA treatment
had dramatic effects on expression of multiple genes involved in glycolysis, the pentose
phosphate pathway, the TCA cycle and gluconeogenesis, as shown in Figure 3.2A.
However, HK-2 was the only glycolytic target gene that was strongly upregulated by
LPA (Figure 3.2).
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Figure 3.2 LPA regulates expression of genes involved in glucose metabolism.
Caov-3 cells were treated with LPA (10 μM) or BSA (vehicle control) for 12 hours.
cDNA was prepared from RNA followed by qPCR array as described in Experimental
Procedures.

3.3.3 HK-2 IS A TARGET OF LPA SIGNALING AND REQUIRED FOR LPA
DRIVEN GLYCOLYSIS
To confirm LPA upregulation of HK-2 expression, we treated Caov-3, OVCAR-3
and OVCA-432 cells with LPA and examined expression of HK-2 mRNA and protein.
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Indeed, LPA upregulated HK-2 mRNA (Figure 3.3A) and protein levels (Figure 3.3B) in
a time dependent manner. While the mRNA levels peaked around 8-12 hours, the protein
levels reached a plateau between 12-16 hours post LPA treatment.

Figure 3.3 LPA upregulates HK-2 mRNA and protein expression in ovarian
cancer cells. A. ovarian cancer cell lines were treated with LPA (10 μM) for indicated
times (hours) and RT-qPCR analysis was carried out to determine HK-2 mRNA
levels. The results were presented as fold increase relative to the mRNA level of
untreated control cells. B. ovarian cancer cells lines were treated with LPA (10 μM)
for indicated numbers of hours before immunoblotting analysis of HK-2 protein and
tubulin (loading control).
The majority of HK-2 protein in a cell is attached to the mitochondria (216) and
mitochondria-associated HK-2 is often regarded as the active form of the enzyme,
contributing significantly to the glycolytic activity (219). LPA increased accumulation of
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both cytosolic and mitochondrial HK-2 (Figure 3.4A). Consequently, LPA dramatically
increased cellular hexokinase activity in ovarian cancer cell lines (Figure 3.4B).
To confirm the biological significance of HK-2 induction by LPA, we
downregulated HK-2 expression induced by LPA in Caov-3 cells with HK-2 siRNA. As
shown in Figure 3.5, we experienced technical difficulty in achieving high levels of HK-2
knockdown, probably due to the necessity of a basal level of HK-2 for cell proliferation
or survival. However, even partial downregulation of HK-2 in Caov-3 cells was sufficient
to significantly reduce LPA-driven glycolysis as shown in Figure 3.5.

Figure 3.4 LPA induces HK-2 expression and cellular HK activity. A. Caov-3 cells
were treated with LPA (10 μM) for 16 hours. Cytosolic and mitochondrial protein
fractions were isolated and immunoblotted for HK-2, VDAC1 (mitochondrial marker)
and tubulin (cytosolic protein). B. Ovarian cancer cell lines were treated with LPA (10
μM) for 16 hours before assaying for hexokinase activity as described in Experimental
Procedures. Hexokinase activity is presented as NADPH (n moles)/mg ptn/min.
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Figure 3.5 Downregulation of HK-2 attenuates LPA-induced glycolysis. Caov-3
cells were transfected with HK-2 siRNA or with non-targeting control siRNA. Cells
were treated with LPA (10 μM) or vehicle and glycolytic rate was measured as
described in Figure. 3.1. Cell lysates were analyzed with immunoblotting to determine
efficiency of HK-2 knockdown.

3.3.4 LPA2 IS THE MAJOR RECEPTOR THAT UPREGULATES HK-2
EXPRESSION AND GLYCOLYSIS
Caov-3, OVCA-432 and other ovarian cancer cell lines express the Edg LPA
receptors LPA1, LPA2, and LPA3 (295), while the non-Edg receptors are either absent or
are expressed inconsistently in ovarian cancer cells (94). Thus to identify the LPA
receptor responsible for the pro-glycolytic effect of LPA, we focused on the Edg LPA
receptors. We used siRNA to knockdown expression of LPA1, LPA2, and LPA3 in Caov3 cells. Only knockdown of LPA2 led to significant inhibition of LPA-induced HK-2
expression and glycolysis. (Figure 3.6A & Figure 3.6B). Similar observations were made
in OVCA-432 cells where LPA receptors were stably knocked down using lentivirusmediated shRNA (Figure 3.6A & Figure 3.6B). These results provided strong evidence
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that LPA2 is the major LPA receptor subtype accounting for LPA-driven HK-2 induction
and glycolysis in ovarian cancer cells.

Figure 3.6 LPA2 is the major LPA receptor subtype responsible for HK-2
induction (A) and glycolysis (B). Each of LPA1-3 receptors was knocked down by
siRNA in Caov-3 cells or by lentivirus-transduced shRNA in OVCA-432 cells. The
cells were treated with LPA (10 μM) or vehicle for 16 hours before immunoblotting
analysis of HK-2 expression (A) and quantification of glycolysis (B).

85

3.3.5 LPA ENHANCES HK-2 EXPRESSION AND GLYCOLYSIS IN A HIF-1Α
INDEPENDENT MANNER
Hypoxia inducible factor (Hif) is the principle regulator of glycolysis under
hypoxic conditions, upregulating expression of most glycolytic enzymes and their
regulators, including HK-2 (233). We wondered if LPA mediated HK-2 induction and
glycolysis are mediated by Hif-1α. We and others have shown that LPA increased Hif-1α
protein levels (260). In addition to HK-2 induction and glycolysis, LPA treatment indeed
increased Hif-1α levels in a time-dependent manner in all ovarian cancer cell lines
examined (Figure 3.7A). However, when Hif-1α expression was downregulated by
siRNA, LPA stimulation of HK-2 mRNA was unaffected in Caov-3 cells (Figure 3.7B).
In contrast, LPA induction of another glycolytic gene, PGK1 (phosphoglycerate kinase-1),
was dramatically reduced by Hif-1a knockdown in these cells (Figure 3.7C). Further, we
examined whether HIF-1α knockdown compromised LPA-dependent glycolysis. As
shown in Figure 3.7D, there was only slight inhibition of LPA-induced glycolysis,
suggesting that LPA promotes glycolysis essentially via a HIF-1α-independent
mechanism.
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Figure 3.7 Hif-1α is not required for LPA induction of HK-2 and glycolysis. A.
Ovarian cancer cell lines were treated with LPA (10 μM) for the indicated periods of
time (hours) before immunoblotting analysis of Hif-1α protein. Hif-1α was knocked
down by siRNA in Caov-3 cells. LPA-induced HK-2 mRNA expression (B), PGK1
mRNA expression (C) and glycolysis (D) were examined and compared between HK2 knockdown cells and non-target control siRNA-transfected cells.
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3.3.6 LPA STIMULATES HK-2 EXPRESSION THROUGH SREBP-1-MEDIATED
TRANSCRIPTIONAL ACTIVATION
Since Hif-1α is not involved in LPA-mediated activation of HK-2 expression, we
next investigated the underlying mechanism by analyzing the human HK-2 gene
promoter. We cloned a fragment (-1476-+73) of the HK-2 promoter into the pGL2-Basic
luciferase reporter vector. Further 5’ deletion generated truncation mutants containing 478-+73 and -273-+73 fragments of the promoter. These luciferase reporter constructs
were transfected into Caov-3 cells and LPA-induced luciferase activity was determined
by luciferase assays. As illustrated in Figure 3.8, LPA treatment led to a robust increase
in luciferase activity in Caov-3 cells transfected with the vector containing the full -1476+73 fragment. The LPA-induced increase in luciferase activity remained intact when the
HK-2 promoter sequence was shortened to -478-+73. However, further deletion to -273+73 resulted in drastic loss of the response to LPA (Figure 3.8), suggesting that the major
regulatory element(s) resided within the sequence between -478 to -273. Insilico analysis
disclosed several potential transcription factor binding sites within this region, including
cAMP-responsive element binding proteins (CREB), Hypoxia inducible factor (Hif-1α),
Nuclear factor 1 (NF1), Kruppel-like factor 7 (KLF7), Specificity Protein 1 (SP1) and
SREBP. The existence of two sterol regulator elements (SRE) within the responsive
region and strong activation of SREBP by LPA prompted us to examine the potential role
of SREBP in transcriptional activation of HK-2. As evident from Figure 3.8, point
mutation of either SRE sites significantly reduced LPA-driven luciferase activity.
Simultaneous mutation of both SRE sites led to a further reduction in the luciferase
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activity but failed to eliminate the response to LPA completely. The remaining activity of
the double mutant was similar to that of the -273 deletion mutant. These results indicated
that the two SREs are necessary regulatory components of maximal activation of the HK2 promoter by LPA.

Figure 3.8 LPA activates the HK-2 gene promoter. Caov-3 cells were transfected
with the indicated reporter constructs and luciferase activities were measured 12 hours
after LPA (10 μM) treatment as described in Experimental Procedures.

3.3.7 LPA INDUCES BINDING OF SREBP-1 TO SRES OF THE HK-2 GENE
PROMOTER
We have recently shown that LPA activates SREBP-1 and SREBP-2 transcription
factors in ovarian cancer cells (295) & Chapter 2. To determine whether SREBP proteins
are indeed capable of binding the SREs of the HK-2 promoter to activate transcription,
we carried out a DNA pull down assay with a DNA sequence harboring the two wild type
SREs (SRE2/3) or their mutated forms (see details of the sequences in Table 3.1). As
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demonstrated in Figure 3.9A, increased binding of nuclear SREBP-1 to the wild type
oligo was detected in LPA-treated Caov-3 cells compared to vehicle control cells. The
LPA-stimulated binding of SREBP-1 was abrogated when the SREs of the oligo were
mutated. In contrast, SREBP-2 was found to nonspecifically bind to both wild type and
mutated oligos, which was not altered by LPA treatment of the cells (Figure 3.9A).
To confirm the binding of SREBP-1 to the native HK-2 gene promoter, we
performed

a

chromatin

immunoprecipitation

(ChIP)

assay.

Following

immunoprecipitation of SREBP-1 from LPA-treated Caov-3 cells, we were able to PCR
amplify a 114 bp fragment corresponding to the region containing the SREs of the HK-2
promoter (Fig. 3.9B). Using the same precipitates, we were unable to amplify another
region around -1478 bp (SRE1). In further support of an essential role of SREBP-1 in
stimulation of HK-2 expression, siRNA knockdown of SREBP-1 in Caov-3 cells
inhibited LPA-induced expression of HK-2 mRNA and protein (Fig. 3.10).
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Figure 3.9 LPA induces SREBP-1 binding to the HK-2 promoter. Caov-3 cells
were treated with LPA (10 μM) for 12 hours. DNA pull-down (A) was performed
using nuclear extracts and biotin labeled oligonucleotides harboring the SREs from the
HK-2 promoter (SRE2/3) or mutated form (SRE2/3 mutated). The SREBP-1 and
SREPB-2 proteins bound to the oligos were examined by immunoblotting. LPAinduced binding of SREBP-1 to the native HK-2 promoter was analyzed with ChIP
assays (B). Two regions containing SRE 2/3 SREs SRE 1, respectively, were PCR
amplified.
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Figure 3.10 SREBP-1 is required for LPA-induced expression of HK-2 mRNA
and protein. Caov-3 cells were transfected with SREBP-1 siRNA or non-targeting
control siRNA. HK-2 mRNA (A) and protein (B) in the cells treated with LPA (10
M) or vehicle for 16 hours were analyzed with RT-qPCR or immunoblotting.

3.3.8 LPA STIMULATES GLYCOLYSIS IN BREAST, COLON AND LUNG
CANCER CELLS: A GENERAL PHENOMENON
Since LPA2, the major receptor that regulates glycolysis in ovarian cancer cells, is
also overexpressed in other types of cancers including breast (108) and colon cancers
(99), we wanted to determine whether LPA could increase glycolysis in these cancer cells.
As shown in Figure 3.14, LPA treatment promoted glycolysis in breast (MDA-MB-231
and MCF-7), colon (DLD-1) and lung cancer cells lines (H838).
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Figure 3.11 LPA activates glycolysis in multiple cancer cell lines. Cells were plated
in 12-well plates and relative fold increase in glycolysis was determined as in
experiments described earlier in ovarian cancer cell lines.

3.3.9 THE LPA2 RECEPTOR AND HK-2 ARE ABERRANTLY
OVEREXPRESSED IN LUNG
A significant finding of our studies described in Chapter 2 and herein (Chapter 3)
is the important role of LPA2 in lipid (Chapter 2) and glucose metabolism (Chapter 3) of
cancer cells. This LPA receptor subtype has been reported to be overexpressed in ovarian,
breast, colorectal and gastric cancers. In this last part of the Chapter, we examined
expression and biological functions of LPA2 in lung cancer, the most common human
malignancy that causes more deaths than any other type of cancer. Non-small cell lung
cancer (NSCLC) cell lines expressed LPA2 mRNA at higher levels than non-transformed
normal human bronchial-epithelial (NHBE) cells (Figure 3.12A). We further compared
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LPA2 expression in lung cancer and in normal lung tissues using the TissueScan™
Cancer and Normal Tissue cDNA Arrays (OriGene). As shown in Figure 3.12B,
expression of LPA2 mRNA was significantly increased in all stages of lung cancers
including Stage I. Consistent with potential regulation of HK-2 via LPA2 signaling, these
lung cancer specimens also showed overexpression of HK-2 mRNA when compared with
normal lung tissues. (Figure 3.12C).
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Figure 3.12 LPA2 and HK-2 are abnormally overexpressed in lung cancer. A. RTqPCR was carried out to determine the relative levels of LPA2 in lung cancer cell lines
and NHBE cells. Expression of LPA2 (B) and HK-2 (C) in primary lung cancer and
normal lung tissues was analyzed using the TissueScan™ Cancer and Normal Tissue
cDNA Arrays (OriGene) as described in Experimental Procedures. For lung cancer
TissueScan™ Cancer and Normal Tissue cDNA Arrays, the Mann Whitney test was
performed to analyze significance between normal and tumor samples, and the
Kruskal-Wallis ANOVA test was carried out to determine significance between
samples of different stages.
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3.4 DISCUSSION
Cancer cells exhibit an altered metabolic profile, exemplified by the Warburg
Effect, which suggests that these cells utilize glycolysis, an inefficient pathway to
generate ATP, instead of the more productive TCA cycle. This seemingly contradictory
route of proliferative cells provides an elevated level of cellular nutrients and biosynthetic
precursors to sustain a high cellular proliferation rate. Intracellular ATP concentration is
often correlated with cell growth, particularly in bacteria, however, the correlation does
not hold in mammalian cells especially tumor cells. Calculations based on cellular energy
requirements clearly indicate that as opposed to unicellular organisms, a majority of
cellular ATP is used to maintain cellular homeostasis in tumor cells (296). Moreover,
cancer cells have been found to consume ATP to drive glycolytic processes and thus
proliferation (297), which is consistent with the observation that high ATP is inhibitory
for glycolytic processes. Thus, targeting this altered metabolic profile is often regarded as
a potential therapeutic strategy for cancer treatment. Although multiple studies have been
focused on understanding the regulation of the glycolytic process, to date no consensus
mechanism has been identified to explain cancer-specific regulation of this process.
In this study, we provide a potential LPA-mediated mechanism for cancer specific
regulation of the Warburg effect. We show that LPA, a bioactive lipid mediator, present
at high levels in ascites of ovarian cancer and other malignant effusions (248,294)
enhanced the glycolytic process in ovarian, breast, colon and lung cancers. This effect of
LPA was cancer specific and undetectable in non-transformed ovarian IOSE-80 and
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breast MCF10A (data not shown) epithelial cells, which lack the LPA2 receptor that is
critically involved in LPA-mediated activation of glycolysis.
This study thus provides evidence that LPA is one of the potential etiological
factors in the tumor microenvironment that maintains hyperactive glycolysis in cancer
cells. Many oncogenic factors and intracellular pathways, such as insulin and the PI3KAKT or RAS-MAPK pathways, are known to enhance glucose uptake in cancer cells,
thereby increasing glucose consumption (292,298,299). On the other hand, LPA does not
increase glucose uptake (data not shown) but strongly enhances glycolysis via
transcriptional activation of HK-2, the enzyme that catalyzes the first step of glycolysis.
HK-2-mediated phosphorylation of glucose not only primes glucose for breakdown to
generate ATP and metabolic intermediates, the step also prevents glucose from exiting
the cell. Therefore, deregulated LPA signaling and other oncogenic pathways such as
PI3K and RAS act in concert to promote distinct steps of glucose utilization in cancer
cells.
Tumors at advanced stages often experience hypoxia, leading to stabilization of
Hif-1α protein, a major regulator of almost all the glycolytic enzymes (233). However,
hypoxia is not the causal factor underlying the glycolytic phenotype that occurs in both
hypoxic and oxygenated regions of a tumor. Tumor cells in vitro also glycolyse when
cultured in normoxic and neutral conditions. Ras, Akt, and c-Myc have been reported to
upregulate expression of various glycolytic enzymes (300,301). In contrast, loss of the
tumor suppressor TP53 inhibits the mitochondrial respiratory chain via suppression of
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SCO2 (the synthesis of cytochrome c oxidase protein) and promotes glycolysis via
TIGAR, a p53-inducible regulator of glycolysis and apoptosis (302). In addition, the
mitochondrial respiratory function can be negatively affected by mutations in
mitochondrial DNA. However, these defects are present only in some of human tumors
and do not explain the generally altered glucose metabolism in a wide spectrum of
cancers. Other unrecognized mechanisms are likely important in the development and
maintenance of the glycolytic phenotype of malignant cells. Here we provided evidence
for regulation of glycolysis in cancer cells by the LPA-LPA2-SREBP-1-HK-2 pathway.
SREBP-1 is a master regulator of lipid metabolism regulating de novo lipogenesis
in liver and in cancer cells (238). We have recently shown that LPA activates SREBP-1
in ovarian cancer cells, thereby leading to an increase in de novo lipogenesis in these cells
(295). Taken together, these studies suggest that SREBP-1 serves as a convergence point
of LPA signaling to regulate both lipid and glucose metabolism in cancer cells.
A major finding of this study is that LPA2, a receptor subtype overexpressed in
many malignancies including ovarian cancer (106,108-111), was the major receptor
promoting glycolysis. LPA1, which is expressed by both normal and malignant ovarian
epithelial cells, was found to be dispensable for the effect of LPA on glycolysis in Caov-3
cells or to have only a minor contribution in OVCA-432 cells. In contrast, silencing of
LPA2 completely inhibited LPA-dependent glycolysis, suggesting a primary role of LPA2
in the process. Given the importance of LPA2 in cancer cell metabolism and the nonessential physiological role of this receptor in mice, inhibition of LPA2 could thus be an
ideal therapeutic strategy against cancer. This study thus provides a novel LPA signaling
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mechanism linked to aerobic glycolysis in cancer cells, which can be exploited for cancer
intervention.
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CHAPTER 4
GENERAL DISCUSSION
In cancer cells, the control of proliferation is perturbed resulting in uncontrolled
cell growth, one of the hallmarks of malignant cells (303). The classical notion of
tumorigenesis is based on the premise that dysregulated oncogenes and tumor suppressor
genes directly regulate cell cycle progression, maintain proliferative signals and help cells
overcome growth suppression and cell death. However, recent advances in cancer cell
metabolism suggest an alternative route for regulation of cell proliferation. Oncogenes
and tumor suppressor genes could alter patterns of cellular metabolism and subsequently
promote cell proliferation. There are several lines of evidences to support this proposition.
A cell must pass though the interphase (G1, S and G2) before it enters the mitotic phase
and cell division occurs. But before a cell divides, intracellular amounts of carbohydrates,
lipids, nucleotides and amino acids must be sufficient for duplication of cellular contents,
including DNA, cellular organelles and membranes. Since intracellular concentrations of
these macromolecules could serve as limiting factors, it is not difficult to imagine the
possibility of metabolic regulation of cell cycle. Yalcin et al. have recently shown that
nuclear

overexpression

of

6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase

isoenzyme 3 (PFKFB3) favors transition from G1 to S phase and this subsequently
upregulates cyclinD3, and M phase-promoting phosphatase Cdc25C, and reduces
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expression of cell cycle inhibitor p27 (304). PFKFBs are enzymes that catalyze
conversion of fructose-6-phosphate to fructose-2, 6-bisphosphate (Fru-2,6-BP), which is
an allosteric activator of phosphofructokinase 1 (PFK1), thereby activating glycolysis.
Consistent with the regulation of transition from G1 through M phase of the cell cycle by
PFKFBs, activation of APC/CCdh1 at the end of M phase has been found to degrade two
critical enzymes involved in cellular metabolism, PFKFB3 and GLS1 (glutaminase 1)
which regulates glycolysis and glutaminolysis, respectively (305). These studies highlight
the roles of metabolic pathways in coordinated regulation of cell cycle.
An altered metabolic profile in cancer has been known for over nine decades
since Otto Warburg’s observation that cancer cells preferentially utilized glycolysis over
oxidative phosphorylation to generate ATP (135). This observation was seen to be a
paradox for quite some time, as glycolysis by itself is an inefficient process for
generation of ATP. Recent observations, however, have demonstrated that the primary
requirement of transformed cells is an abundance of precursors for biosynthetic processes,
which are provided by a high glycolytic rate (193). It can thus be said that the
requirement for ATP is secondary to that for intracellular biosynthetic precursors,
providing an explanation for the paradoxical use of glycolysis by cancer cells. The
heightened influx of carbon (as glucose), is utilized by transformed cells to generate fatty
acids by de novo lipid synthesis. The fatty acids not only serve as precursors for protein
lipidation reactions and as secondary messengers, they are also major constituents of cell
membranes. Since a rapidly proliferating cell requires large amounts of membrane
constituents for intracellular organelles and for plasma membranes, de novo lipogenesis is
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often found to be a determinant in regulating cell proliferation and survival
(147,151,153,306,307). Thus hyperactive glycolysis and enhanced de novo lipogenesis
are two hallmarks of cancer cells.
Although growth factor mediated proliferation of cancer cells has been studied in
detail, most of the focus has been on signaling from the receptor tyrosine kinases (such as
EGFR, ERB2, PDGF, FGF and insulin receptor). Only recently, with the discovery of
overexpressed GPCRs and their ligands in cancer, GPCR-mediated regulation of cell
proliferation is being considered an important regulatory mechanism. One such class of
GPCR ligands are bioactive phospholipids, such as LPA, and it related cousin
sphingosin-1-phosphate (S1P). LPA is known for its role as an oncogenic lipid regulating
various cellular processes including cell proliferation (36). Seven GPCRs for LPA have
been identified to date, and both LPA and some of its receptors have been found to be
upregulated in cancer. Our lab was the first to show overexpression of LPA2 and LPA3 in
ovarian cancer (107,120), and subsequently several labs have provided evidence for
overexpression of LPA2 in various other malignancies. LPA2 couples to Gαi, Gαq and
Gα12/13 G-proteins. Pertussis toxin sensitive Gαi-driven signaling has been shown to
regulate LPA-mediated cell proliferation (118,120). Downstream of Gαi, the Ras-MAPK
and the PI3K-AKT pathways have been shown to be involved in LPA induced cell
proliferation (120,125). However, no conclusive mechanism has been elucidated that
would explain how LPA regulates proliferation of cancer cells. In this study we wanted to
determine if LPA had an effect on cancer cell metabolism and if this could explain the
mitogenic role of LPA.
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Since de novo lipogenesis has a direct impact on the cell cycle, we wondered if
LPA could activate this process in cancer cells. As a model system, we chose ovarian
cancer, as LPA mediated effects have been studied in great detail in this cancer type. We
observed a dramatic increase in LPA mediated lipogenesis in ovarian cancer cells.
However, LPA failed to activate this process in non-transformed cells, suggesting a
cancer-specific action of LPA. This increase in lipid synthesis was not due to the increase
in cell numbers as the results were normalized to the activity of a fixed numbers of cells.
The lipid contents within cells were also increased dramatically after LPA treatment, as
visualized by BODIPY 493/503 staining of neutral lipids and biochemical quantitation of
different classes of intracellular lipids. It is important to note that the most significant
increase in lipids was detected as TAG. There was also less dramatic increase in the
content of phospholipids, which correlated with increases in cell number. Liver and
adipogenic tissues are known to accumulate fat as lipid droplets which can then be
broken down by β-oxidation to release energy. Such a mechanism can provide
considerable advantages to cancer cells, such as reducing their dependence on growth
factors and energy production, and promoting self-sufficiency as observed in co-culture
experiment of adipocytes and cancer cells (308). Indeed, several studies have shown that
there is increased lipid accumulation in breast (309), brain (310), lung metastasis (311)
and in adenomas of the adrenal gland (312). Moreover, accumulation of lipids in cells in
proximity to cancer cells has an indirect effect on carcinogenesis; for examples, lipid
accumulation in dendritic cells has been shown to promote cancer metastasis (313).

103

Similar to lipogenic tissues (liver or adipose tissue), LPA mediated lipogenesis in
cancer cells was found to be regulated by activation of SREBP proteins. In most cancer
cell lines we analyzed, LPA was found to activate SREBP proteins by facilitating
proteolytic cleavage of their precursor forms. Since both SREBP-1 and SREBP-2 are
activated in a similar manner, LPA treatment led to the accumulation of mature forms of
both proteins in nuclei. LPA-induced activation of SREBP proteins is sufficient to
increase expression levels of critical lipogenic targets of SREBP proteins - SREBP-1
mediated FAS and ACC and SREBP-2 mediated HMGCoA reductase. Unlike activation
of SREBP proteins by receptor tyrosine kinases (RTK), LPA induced activation of
SREBP and lipogenesis was found to be dependent on the Rho-Rock pathway. This is the
first report that implicates the Rho-Rock pathway in the activation of SREBP. This
observation is significant as it indicates that multiple SREBP-activating pathways need to
be inhibited to block SREBP-dependent lipogenesis in cancer cells.
The exact mechanism by which LPA activates SREBP proteins remains to be
fully elucidated. We hypothesize that LPA facilitates transport of SREBP proteins from
the ER to the Golgi, where constitutively active proteases S1P and S2P process SREBP
to release its active form. This effect of LPA could be achieved by increasing the ratio of
SCAP to INSIG proteins in cells. It will be interesting to test this hypothesis when
appropriate antibodies against SCAP and INSIG become commercially available.
Lipogenesis is regulated at multiple levels. One such critical regulator is the
serine threonine kinase AMPK, which is known to be activated by an increase in the
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AMP: ATP ratio, indicative of reduced ATP levels in cells. AMPK is a master regulator
that shuts down anabolic processes to activate energy yielding catabolic processes. It is
known to inhibit lipogenesis by targeting various components of the pathway with the
most classical target being ACC. Active AMPK phosphorylates ACC at Ser-79 to inhibit
its activity, thereby attenuating lipogenic processes. Consistent with the activation of
lipogenesis, LPA treatment was found to inhibit AMPK phosphorylation in a Gq-PLC
dependent manner. LPA was also found to modestly reduce AMP: ATP levels, a possible
mechanism leading to inactivation of AMPK in LPA-treated cells.
A significant finding of this study was the identification of LPA2 as the major
receptor regulating these processes. LPA2 is the Edg LPA receptor known to be most
often overexpressed in various cancer types including, ovarian cancer. The cell lines used
in the study express several fold higher level of LPA2 than non-transformed IOSE-29
cells. This could explain the LPA2-specific activation of SREBP proteins and lipogenesis
in ovarian cancer cells. It was interesting that LPA2-mediated these processes selectively
in the presence of other co-expressed receptors. In particular, although highly expressed
in OVCA-432 cells, LPA3 was not involved in LPA-mediated lipogenesis. On the
contrary, downregulation of LPA3 was consistently associated with slight potentiation of
LPA-induced lipogenesis, indicating possible crosstalk between LPA2 and potentially
negative LPA3 in modulation of the lipogenic response to LPA.
Another question we asked is whether LPA mediated cell proliferation depended
on de novo lipogenesis. We inhibited lipogenesis in ovarian cancer cell lines by targeting
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critical lipogenic enzymes FAS and ACC that were upregulated by LPA treatment.
Chemical inhibitors and molecular approaches against these two proteins led to complete
attenuation of LPA-induced cell growth. Also, since LPA2 was the receptor responsible
for the LPA-driven lipogenesis, inhibition of LPA2 also caused a dramatic reduction of
cell proliferation. These results indicate a causal role for de novo lipid synthesis in LPAdriven cell proliferation. Hence LPA signaling, especially LPA2 receptor linked to
activation of lipogenic enzymes, can be targeted as possible therapeutic approaches
against cancer.
Since de novo lipogenesis is an important determinant in LPA driven proliferation,
we extended the study to understand the lipogenic phenotype of cancer cells. The first
step of fatty acid synthesis involves carboxylation of acetyl-CoA to malonyl-CoA, which
is carried out by ACC. FAS then carries out the next steps of synthesis, generating long
chain fatty acids by the subsequent addition of 2 carbon units. Acetyl-CoA thus acts as
the limiting factor in this process, and so cells need to increase acetyl-CoA levels in the
cytosol for lipogenesis to proceed. One of the primary routes for generation of acetylCoA is by glucose metabolism. Pyruvate generated via glycolysis is converted into
acetyl-CoA by the pyruvate dehydrogenase complex in mitochondria. Since acetyl-CoA
cannot exit the mitochondria, it is used to generate citrate, which can exit the
mitochondria and is then converted to acetyl-CoA in the cytosol by ATP citrate lyase.
Hence, the rate of glycolysis can control lipogenesis in cells, and not surprisingly cancer
cells are known to have hyperactive glycolysis. We thus asked if LPA can activate
glycolysis in cancer cells to ultimately lead to an increase in lipogenesis.
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LPA treatment was found to dramatically activate glycolytic processes in cancer
cells; this effect was not seen in non-transformed cells (IOSE-80 and MCF-10A), an
observation similar to LPA mediated regulation of lipogenesis. This indicated that LPA
regulated both lipogenesis and closely associated glycolytic metabolism. As a
consequence of increased glycolysis, treatments with LPA lead to concomitant lactate
efflux from cells, which were again observed only in cancer cells. Lactate efflux leads to
acidification of the tumor microenvironment, favoring tumor cell invasion (196) and
immune modulation (197) which facilitates tumor growth. Hyperactive glycolysis is often
associated with enhanced glucose uptake mediated by increased expression of glucose
transporters (such as Glut1). Glucose uptake has been shown to be upregulated by Hif-1α,
c-Myc, and ATK (298,314,315). Although growth factors including LPA have been
shown to regulate all of these mediators, the LPA-mediated increase in glycolysis could
not be explained by changes in Glut1 expression. In fact, LPA did not increase glucose
uptake in ovarian cancer cell lines (data not shown). Instead, our results demonstrate that
LPA enhances glycolysis through transcriptional activation of HK-2, one of the
glycolytic genes widely upregulated in cancers (219). This increase in HK-2 levels was
functionally sufficient to promote glycolysis in cancer cell lines.
Using an RT-PCR array, we were able to profile transcriptional changes in
glycolytic genes induced by LPA. The effect of LPA was not limited to glycolysis as
LPA was found to alter mRNA levels of genes involved in various pathways of glucose
metabolism including gluconeogenesis, the TCA cycle, the pentose phosphate pathway
and glycogen metabolism. In was interesting to observe that there was a concomitant
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reduction in transcripts of several genes involved in the TCA cycle such as malate
dehydrogenase 1B (MDH1B), pyruvate dehydrogenase kinase 2 (PDK2) and pyruvate
dehydrogenase kinase 4 (PDK4). It remains, however, to determine if LPA treatment
inhibits the TCA cycle in cancer cells. Consistent with the role of LPA in activation of
biosynthetic processes, genes involved in the reductive pentose phosphate pathway (PPP),
such as phosphoribosyl pyrophosphate synthetase 1-like 1 (PRPS1L1) and Ribose-5phosphate isomerase (RPIA), were also upregulated based on the data of RT-PCR array,
which could lead to regeneration of glycolytic intermediates. However, the most
significant effect of LPA on glucose metabolic genes was found to be on HK-2.
HK-2 is a well-established target of Hif-1α and c-Myc transcription factors
(237,316). In this study, LPA increased HK-2 expression in cancer cells via SREBP-1
transcription factors, which are master regulators of fatty acid synthesis. Regulation of
HK-2 by SREBP-1 is not an unknown phenomenon. There have been a few studies that
connect SREBP activation to HK-2 expression. SREBP-1 has been reported to bind to the
HK-2 promoter and activate its expression in human myocytes (317,318) and in rat liver,
adipose tissue, and skeletal muscle. (319). However, SREBP-1 regulation of the HK-2
promoter activity and expression has not been observed in cancer cells. Here we show
that LPA induced SREBP-1 binding to the -340 to -296 region of the HK-2 promoter,
leading to its transactivation. It was interesting that this region had two potential SREs
(SRE 2/3), located very close to each other. Mutation of either of the two sites impaired
LPA-induced HK-2 promoter activity, indicating that both SREBP-1 sites contribute to
optimal activation of the HK-2 promoter in LPA-treated cells. It is also possible that the
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two closely linked SREs form a complex with more than one molecule of SREBP-1.
Although SREBP-1 functions as the major transcription factor driving HK-2 expression
in response to LPA, our mutational analysis of the HK-2 promoter suggest possible
involvement of other transcriptional factors that could contribute to LPA- induced HK-2
expression, as the double SRE mutant remained partially responsive to LPA treatment.
In our study, LPA-mediated glycolysis was found to be independent of Hif-1α.
Hif-1α is the principal regulator of hypoxia-mediated gene regulation. Hif-1α has been
shown to play a major role in regulation of glycolysis in hypoxia. However, hyperactive
glycolysis occurs in tumor cells in both hypoxic and normoxic conditions. Although
oncogenic pathways such as PI3K (320,321), mutations in VHL (230), succinate
dehydrogenase (SDH) (231) and fumarate hydratase (FH) (232) have been shown to
stabilize Hif-1α under normoxic conditions, the amount of Hif-1α generated by these
effects may not be enough to elicit a transcriptional response, and the majority of tumor
samples possess modest amounts of Hif-1α (322). Thus, alternative pathways might exist
that could activate glycolysis under normoxic conditions. LPA, by an unidentified
mechanism, does lead to stabilization of Hif-1α proteins, but its effect on glycolysis was
found to be independent of Hif-1α. These observations indicate that LPA could be one of
the causative factors underlying the glycolytic phenotype of cancer cells under normoxic
conditions.
Another significant finding from this study was the regulation of LPA-induced
HK-2 expression and enhanced glycolysis by LPA2, providing yet another piece of
evidence for coupling of glycolytic and lipogenic processes via a co-regulator.
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Interestingly, LPA2 and to some extent LPA1, contributed to stabilization of Hif-1α
proteins (data not shown), yet the mechanism involved in activation of glycolysis was
found to be independent of Hif-1α protein. Our lab has previously demonstrated that
LPA-mediated upregulation of VEGF an established Hif-1α target, in ovarian cancer cells
is independent of Hif-1α (260). These studies point to alternative Hif-1α-independent
pathways mediated by LPA receptors as critical mediators of carcinogenesis. Moreover
we provided evidence that the glycolytic effect of LPA was not limited to ovarian cancer.
The effect was also observed in cancers of breast, colon and lung. The general effect of
LPA in these cancers is consistent with overexpression of the LPA2 receptor in these
cancers. LPA2 expression in lung cancer has not been studied previously. We here
showed for the first time that LPA2 is overexpressed in lung cancer cell lines as well as in
primary lung carcinomas. Further, LPA induced expression of HK-2 and glycolysis in
lung cancer cell lines.
Taken together, the results presented in this thesis provide compelling evidence
that LPA induces both de novo lipid synthesis and glycolysis in diverse types of cancer
cells. These effects of LPA are mediated by LPA2, an LPA receptor subtype
overexpressed in many types of human cancers. We have also presented evidence that
LPA induction of lipogenesis and glycolysis in cancer cells is an integral component of
the cellular proliferative program. Thus our studies have elucidated a novel role of LPA
and its receptor LPA2 in regulation of cancer cell metabolism and cell proliferation.
These studies therefore open a new avenue for research in LPA and cancer cell biology.
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